Next Article in Journal
Salvianolic Acid A Activates Nrf2-Related Signaling Pathways to Inhibit Ferroptosis to Improve Ischemic Stroke
Previous Article in Journal
A Comprehensive Study of the Cobalt(II) Chelation Mechanism by an Iminodiacetate-Decorated Disaccharide Ligand
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds—Part 1: Aromatic Frameworks

A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, Favorsky Str. 1, 664033 Irkutsk, Russia
*
Author to whom correspondence should be addressed.
Molecules 2025, 30(15), 3264; https://doi.org/10.3390/molecules30153264
Submission received: 2 July 2025 / Revised: 23 July 2025 / Accepted: 31 July 2025 / Published: 4 August 2025

Abstract

This review summarises the possible applications and basic methodologies for the synthesis of six-membered polyazo heterocycles, namely, diazines, triazines, and tetrazines. The time period covered by the analysed works ranges from the beginning of the 20th century to the present day. This period was chosen because it was during this time that synthetic chemistry, as defined by physicochemical research methods, became capable of solving such complex problems as efficiently as possible. The first part of the review describes the applications of polyazo heterocyclic compounds, whose frameworks are found in the composition of drugs, dyes, and functional molecules for materials chemistry, as well as in a wide variety of natural compounds and their synthetic analogues. The review also systematises the methods for assembling six-membered aromatic polyazo heterocycles, including intramolecular and sequential cyclisation, which determine the possible structural and functional diversity based on the presence and arrangement of nitrogen atoms and the position of the corresponding substituents.

1. Introduction

Nitrogen is one of the essential elements which, being a part of natural compounds, provides functional diversity. A special place among nitrogen-containing compounds is occupied by polyazo heterocycles, which can undoubtedly be called an indispensable attribute of life. Such heterocycles provide oxygen transport in organisms (e.g., chlorophyll and hemoglobin) and transfer hereditary information (e.g., the nitrogenous bases of DNA and RNA), which makes reproduction and evolution of life possible.
A close look at natural molecules with azaheterocyclic scaffolds (apart from the aforementioned compounds, these include vast libraries of alkaloids that regulate activity of virtually all types of organism), drugs, dyes, and advanced materials reveals that such systems are mainly represented by polyazo annulated heterocycles. In addition to their use in drug development and advanced technology materials, N-heterocyclic compounds are also in demand in synthetic chemistry due to their reactivity. Therefore, it is not surprising that the development of modern approaches to the synthesis of polyazo annulated heterocycles is an urgent task for the global synthetic community.
The chemistry of polyazocyclic compounds has recently been the subject of active development. The synthesis of diazine, triazine, and tetrazine derivatives allows the discovery of new drugs and preparation of high-energy systems. Nitrogen-containing heterocycles are important because they often form the basis of many pharmaceutically and agrochemically active compounds. The search for new materials with high energy density is being conducted among hybrid compounds, i.e., substances that incorporate different nitrogen-containing heterocycles. Researchers believe that combining different heterocycles into one molecule endows it with new, useful properties. Polyazo heterocyclic compounds constitute an important area of organic chemistry. Nitrogen heterocycles have been found to mimic various endogenous metabolites and natural products, emphasising their key role in the development of modern drugs. They have diverse applications and are predominantly used as pharmaceuticals, corrosion inhibitors, polymers, agrochemicals, dyes, and developers. Their catalytic behaviour makes these compounds notable precursors in the synthesis of various important organic compounds.
The present literature review summarises works that describe polyazo compounds based on six-membered aromatic heterocycles and their applications and methods of preparation. Given the diversity and volume of existing literature data, the proposed systematisation seems to be the most effective method of presentation.

2. Application of Six-Membered Polyazocyclic Compounds

2.1. Diazines

Diazines are six-membered heterocyclic compounds containing two nitrogen atoms: pyridazines, pyrimidines, and pyrazines (Figure 1). This section summarises the literature data on their applications and methods of preparation. The diverse biological activities of diazines are well documented in research papers and reviews [1,2,3,4,5,6,7].
Due to their wide range of biological properties, including antiviral [8,9], antifungal [10], antimicrobial [11,12,13,14,15], anticancer [16], antitubercular [17], anti-inflammatory [18], antibacterial [19,20,21], antidiabetic [22], and others [23,24,25], pyridazine analogues have long been of interest for both medicine and agriculture [26,27,28,29].
The pyridazine structural motif is a popular pharmacophore and is found in some drugs, such as the fourth-generation cephalosporin antibiotic Cefozopran and the psychotropic drug Minaprin. Optivar (azelastine hydrochloride) is indicated for the treatment of itchy eyes associated with allergic conjunctivitis [30]. Aprésolien (hydralazine) and its analogue Cadralazine are antihypertensive vasodilators [31]. Digihydralazine® is used to treat hypertension [32] (Figure 2).
Pyridazine core is also met in several herbicides, including Credazine, Pyridafol, and Pyridate. It is incorporated in metal complex ligands that can be applied as active electrocatalysts for proton reduction [33,34,35]. The electrochemical and photophysical properties of new organic light-emitting diodes containing the pyridazine acceptor part have been studied [36]. [1,2,5]-Thiadiazolo [3,4-d]pyridazines are used as internal acceptors for sensitisers [37]. Pyridazine scaffold is of great importance in optoelectronics because of its highly fluorescent properties, and it can be employed as sensors, biosensors, electroluminescent materials, lasers, and semiconductor devices [38,39,40,41,42].
Some pyrimidine analogues exhibit a variety of properties, including antiviral [43], antibacterial [44,45,46], anticancer [47], antidiabetic [48], antiparasitic [49], anticonvulsant [50], and others [51]. They also act as antidepressants [52] and analgesics [53].
The best-known drug containing a pyrimidine fragment is Acyclovir [54,55], which was the first effective antiviral agent to be discovered. Valacyclovir, which is also available on the market under the brand name Vitrax, was derived from Acyclovir [56]. Rosuvastatin (Crestor) is a fourth-generation hypolipidaemic drug that inhibits cholesterol synthesis [57]. Allopurinol (Zyloprim) is mainly used to treat hyperuricaemia (elevated uric acid levels in the blood) and its complications [58]. Risperidone is effective in therapy of Alzheimer’s disease and substance abuse disorders [59]. Pyrrolopyrimidines are efficient antitumour drugs. For instance, Ruxolitinib is indicated for the treatment of myelofibrosis [60], Ribociclib is recommended against breast cancer [61], and Pemetrexed is used in therapy of non-small cell lung cancer [62,63]. Tubercidin inhibits the growth of certain bacterial strains [64]. Toyocamycin is a well-known antitumour antibiotic [65,66] that is active against L1210 leukaemia, P338 leukaemia, and Lewis lung carcinoma. It has also been tested in clinical trials for use against colon cancer, gallbladder cancer, and acute myelogenous leukaemia in humans [67] (Figure 3).
Pyrimidines are used as building blocks for aromatic [68] and partially aromatic compounds [69,70], in biorthogonal reactions [71], as flavouring agents [72], luminescent materials [73], and in combination with metal ions for design of highly structured molecular architectures [74]. Pyrimidine-based oligomers were investigated for their optical absorption and emission properties and for utilisation as a pH indicator [75]. Photoreactive surfaces were prepared by attaching pyrimidine molecules to planar gold substrates to form films [76]. It was shown that a series of carbene systems of palladium ligands was effective in the activation of methane and in the Mizoroki–Heck reaction [77].
Pyrazines are known to exhibit antitumour [78], antibiotic, anticonvulsant, antitubercular, and other activities [6,79,80,81,82,83,84]. They also possess antimicrobial and anti-inflammatory properties [85].
Pyrazine derivatives are pharmacologically active. Pyrazinamide is a well-known antitubercular agent [86]. Glipizide and Sitagliptin (Januvia) are efficient against diabetes [87], and Amiloride is used as a diuretic [88]. Bortezomib and Oltipraz are indicated for therapy of cancer [89]. Sildenafil (Viagra) is used to treat erectile dysfunction, pulmonary arterial hypertension, and other diseases [90]. Studies on the efficacy of this drug in Alzheimer’s disease are also known [91]. Doxazosin (Cardura) is a non-selective alpha-1-adrenergic antagonist (alpha-adrenoblocker) employed in the therapy of arterial hypertension and benign prostatic hypertrophy [92]. Levofloxacin (Levaquin) is the antibiotic against bacterial infections [93]. It was also approved for the management of H. pylori-associated out-of-hospital pneumonia [94]. Ciprofloxacin is a broad-spectrum antimicrobial agent belonging to the fluoroquinolone group of antimicrobials [95,96]. Ketoconazole (Nizoral) is primarily employed in the treatment of fungal skin infections [97]. Trazodone is a drug efficient against depressive and anxiety disorders [98] and it is also used in the treatment of insomnia [99]. Aripiprazole (Abilify) is an atypical antipsychotic medication that can be employed for the treatment of Tourette’s syndrome [100]. Hydroxyzine (Atarax) reduces central nervous system activity and is used as a sedative [101,102]. Zopiclone is a non-benzodiazepine sleep-inducing pharmaceutical agent used for the short-term treatment of insomnia [103]. Meclizine (Bonine) is used to treat vestibular disorders [104]. Some of these drugs are depicted in Figure 4.
Pyrazines are used in agriculture as insecticides [105]. Some pyrazine derivatives are employed as flavouring and colouring agents in food products [106]. Additionally, quinoxaline compounds were appraised for utilisation as bulk heterojunction solar cells [107] and characterised as functionalised p-conjugated dendrimers with electronic applications [108]. Moreover, different types of polypyrazine derivatives are also used in the polymer industry as conjugated polymers [109] and semiconductors [110]. n-Type polymeric semiconductors based on dithienylpyrazindiimide were reported [111]. The polyimides constructed from a pyrazine moiety and cured at a low temperature find application in the modern microelectronics [112]. The fused ring pyrazine core impacts the thermal, electronic, and optical properties, as well as the thin film morphology, of organic field-effect transistors [113]. The utilisation of pyrimidine and pyrazine bridges as a design strategy was demonstrated to enhance the performance of thermally activated organic light-emitting diodes with delayed fluorescence [114,115].

2.2. Triazines

Triazines represent an important class of six-membered aromatic heterocycles comprising three nitrogen atoms. There are three types of triazine regioisomers (Figure 5). 1,2,4-Triazines, also known as a-triazines, are an asymmetric subset of triazines. Among the three classes of triazines, 1,2,4-triazines are the most studied.
Biological activity of the compounds bearing a triazine structural motif is surveyed in reviews [116,117]. For instance, a series of 1,3,5-triazine derivatives exhibit antiviral activity that is higher than that of moroxidine hydrochloride [118]. The 1,2,4-triazine ring is frequently met in many natural or synthetic biologically active compounds with a wide variety of pharmacological properties. They are especially active as antitumour [119] and anti-AIDS agents [120], CRF receptor antagonists [121], antimicrobials, and anti-inflammatories [122]. A range of synthetic analogues of 1,2,3-triazine have been shown to possess biological activities, including antitumour [123], antimicrobial [124,125], antiviral [126], analgesic [127], anti-inflammatory [128], antihistamine [129], antiangiogenic [130], and antifungal [131].
A plethora of drugs are based on triazine moieties. For example, Altretamine, an antitumour agent, is employed in the management of persistent or recurrent ovarian cancer [132,133,134,135]. Oteracil is a chemotherapeutic agent, which is used in combination with other pharmaceuticals for the treatment of advanced gastric cancer [136] and nasopharyngeal cancer [137]. Tretamine is an antitumour medicine that is utilised in the therapy for retinoblastoma [138]. Lamotrigine (Lamictal) is an antiepileptic drug to combat certain types of epilepsy and type I bipolar disorder [139]. Tirapazamine, also known as SR-4233, is an experimental anticancer drug [140], Azaribine is an antiviral agent [141], and Remdesivir (whose framework is pyrrolo[2,1-f][1,2,4]triazine) is an antiviral medicine [142] (Figure 6).
1,3,5-Triazines also play a prominent role in fluorescent chemosensor applications [143]. These compounds and their nitrogen-containing heterocyclic derivatives have key structural features with a wide range of photovoltaic characteristics and find application as UV absorbers, fluorescent probes, and phosphorescent organic light-emitting diodes [144,145,146]. Triazines are used as herbicides and pesticides, including atrazine, simazine, and cyanazine [147].

2.3. Tetrazines

Tetrazines represent an important and sought-after class of N-heterocycles that find applications in various fields of human activity among the three possible isomers (Figure 7).
Tetrazines are utilised as synthons in the synthesis of various alkaloids. For instance, lycorine possesses analgesic, antipyretic, and anti-inflammatory properties. The alkaloid hippadine exhibits cytotoxic activity against a number of tumour cells, whilst epibatidine is a potent analgesic [148]. 1,2,3,4-Tetrazines have anticancer and antimicrobial properties [149,150,151].
The antitumour drug mitozolomide was synthesised on the basis of imidazotetrazine. Further development of this pharmaceutical product was discontinued during phase II clinical trials, as the recommended dose proved was found to be too toxic, causing severe thrombocytopenia. Temozolomide proved to be less effective but less toxic than mitozolomide. It is currently marketed under the trade name Temodal (Temodar and Temomedac) and is used against malignant melanoma, mycosis fungoides, and brain tumours [152,153,154,155] (Figure 8).
In addition to their biological applications, tetrazines and their 3,6-disubstituted derivatives are of great interest to the field of coordination chemistry. They are characterised by unusual transfer of electron density and charge and the ability to coordinate metal centres through multiple mechanisms [156]. As an electron-deficient 4π-component, they participate in Diels–Alder reverse electron-transfer reactions [157]. Tetrazines are employed in the synthesis of energetic materials with a high nitrogen content [158,159]. Tetrazino-tetrazine-1,3,6,8-tetraoxide is considered to be one of the most potent energetic materials that has been synthesised to date [160]. Tetrazines conjugated to tetrazole are versatile bifunctional building blocks for the synthesis of linear oligoheterocycles [161]. Tetrazines linked to pyridine open access to substituted pyridazines, which are known for their high ability to coordinate metals [162]. Tetrazine-based metal–organic frameworks find applications in small molecule adsorption, sensing, and in the detection of organic functional molecules [163]. Tetrazines are utilised for the development of chromophoric nucleosides to produce coloured uridines ranging from purple to orange and red [164].

3. Synthesis of Six-Membered Polyazocyclic Compounds

The methods for assembly of six-member polyazo aromatic systems, namely, diazines, triazines, and tetrazins, as well as structures containing pyrrole condensed frameworks, starting with diazine structures, will be successively considered. Literature analysis shows that the main strategies for design of the above systems are (1) catalysis of transition metal complexes, both in the presence of specially introduced ligands and in the ligand-free version; (2) direct synthesis of polyazotic aromatic heterocycles, carried out in the presence of (i) strong organic bases, (ii) organocatalysts, under the influence of (iii) microwave or ultrasonic radiation, as well as (iv) electrochemically. Considering the significant role of pyrrolo-fused in pharmaceutical and material science, some methods for their production were considered. It should be noted that, in this part of the review, we will only discuss six-membered polynitrogen systems having aromaticity.

3.1. Synthesis of Diazine Derivatives

3.1.1. Synthesis of Pyridazine Derivatives

To date, a plethora of syntheses of chemically and pharmacologically valuable pyridazines have been developed. A variety of synthetic methodologies for the construction of pyridazine systems [165,166,167], including pyrrolopyridazines [168], were comprehensively documented in the literature. The pioneering data were obtained by Curtius [169] using the reaction of diethyl-1,2-diacetylsuccinate with hydrazine hydrate as an example. Consequently, an in-depth investigation of this reaction was initiated. The majority of general methods for the synthesis of pyridazines involves the condensation of 1,4-dicarbonyl compounds 2 with hydrazine 1 and its derivatives (Scheme 1) [170,171,172,173,174].
One of the general methods for the preparation of pyridazines has been known since 1972; the work of Meresz et al. [175] described the Diels–Alder reaction using 1,2,4,5-tetrazines as dienes and alkynes [176,177,178]. In a similar manner, 1,2,3-triazines were found to react with 1-propynylamines under neutral conditions [179]. Scheme 2 shows the general method for the synthesis of pyridazine derivatives 4 from tetrazines 3 via the Diels–Alder reaction.
Other methods for the synthesis of pyridazines include annelation of aldehyde hydrazones with α,β-unsaturated nitriles [180,181]; alkoxyallenes with 1,2-diaza-1,3-dienes [182]; ketene with N,S-acetals and N-tosylhydrazones [183]; cyclopropene derivatives with hydrazones [184]; catalytic three-component one-step annelation [185,186]; and multistep synthesis using the Diaz–Wittig reaction [187]. The cyclisation of alkynones 5 with indium(III) triflate-activated hydrazine afforded substituted pyrazines 6 (Scheme 3). When substrates containing a benzoyl or tosyl group were used as R2, this group was removed to form 4-substituted products [188].
Under microwave irradiation, dibenzyl 7 reacted with cyanoacetohydrazide to give 3-oxo-5,6-diphenyl-2,3-dihydro-pyridazine-4-carbonitrile 8 (Scheme 4). The microwave irradiation method gave better yield and needs short reaction time [189].
Pyridazines can be obtained by the recyclisation involving either the compression [190] or expansion of the diazepinone cycle [191]. Pyrrolopyridazine derivatives were first obtained by Flitsch and Krämer in 1968–1969; pyrrolo [1,2-b]pyridazines were synthesised from 1-aminopyrrol and its derivatives [192,193]. The synthesis of pyrrolo[1,2-b]pyridazine derivatives was reported in 1977 by Kuhla and Lombardino [194]. Pyridazines containing a pyrrole backbone are synthesised in a multistep manner [195]. The first step includes the functionalisation of the pyrrole backbone 7 at the nitrogen atom and then to the second position of the pyrrole ring 8. After that, pyrrolo[1,2-b]pyridazines 10 were readily obtained via a domino-coupling–isomerisation–condensation reaction between 9 and the corresponding (hetero)arylpropargyl alcohols (Scheme 5) [196].

3.1.2. Synthesis of Pyrimidine Derivatives

A number of reviews are devoted to the synthesis of pyrimidines [197,198]. For instance, the work by Pino-González surveys catalytic methods of preparation [199]. Pyrimidines are generally formed via a three-component reaction between aldehydes, ketones, and various amidines [200,201,202,203,204,205]. The use of a catalyst in the reaction allows the synthesis of substituted pyrimidines without organic solvents [206]. This section deals with other methods for the synthesis of pyrimidines.
Pyrimidines 12 were obtained under microwave irradiation of a mixture of 11, formamide, and phosphorus oxychloride (Scheme 6). The one-pot microwave-assisted synthetic protocol is high-yielding, ecofriendly, and eliminates intermediate workups [207].
Rostovskii [208] studied a novel photolysis of α-azidocinnamates, leading to the key intermediate 2H-azirines, which underwent the dimerisation ring-expansion cascade to produce fully substituted pyrimidines. For dimerisation involving 2H-azirine via a Pd/Ag cocatalysed intermolecular self-assembly, a wide variety of unsymmetrical tetra-arylsubstituted pyrimidines efficiently give a wide variety of moderate yields [209].
Pyrimidines 14 were synthesised by the reacylisation of indoles 13. The reaction was carried in LiHMDS under mild conditions (Scheme 7a). The same reaction was applicable to 1H-pyrroles 15 (Scheme 7b), which, in the presence of PIFA as an oxidising agent, gave compounds 16 [210].
The electro-oxidative formal [3+3] annulation of 1,3,5-triazinane 17 with enamines 18 affording polysubstituted 1,2-dihydropyrimidines 19 was implemented (Scheme 8) [211]. It was noted that the reaction was carried out under mild conditions without transition metal compounds to give the target products in excellent yields.
In regard to pyrrolo[1,2-a]pyrimidines, methods for the preparation of these compounds can be categorised into three groups: syntheses starting with the preliminary formation of the pyrimidine part of the bicyclic system; syntheses starting with the preliminary formation of the pyrrole part; and syntheses from acyclic reagents only. A limited number of functional group transformations, such as esterification and nitrile hydrolysis, were documented for derivatives of the completely unsaturated pyrrolo[1,2-a]pyrimidine core. However, the reactions described for pyrrolo[1,2-c]pyrimidines fall into three main types: electrophilic attack, addition reactions, and cycle opening processes. It was disclosed [212] that the cyclocondensation of 20 with tosylmethylisocyanide followed by desulfonylation of 2-tosylpyrrolo[1,2-c]pyrimidines 21 with sodium amalgam afforded pyrrolo[1,2-c]pyrimidines 22 (Scheme 9).
A series of pyrrolo[1,2-a]pyrimidines 25 containing 1,3-indanedione skeleton (Scheme 10) was obtained by bicyclisation from triethylammonium thiolates 23, methyl iodide, and 24 [213]. The unique property of this method is a simple procedure without using any metal catalysts or acid/base additives.
A wide range of asymmetrically tetrasubstituted fused pyrrolo[1,2-a]pyrimidines 28 was obtained from NH-pyrroles 26 and diketones 27 and Scheme 11 shows the synthesis [214].

3.1.3. Synthesis of Pyrazine Derivatives

There are many methods for the synthesis of pyrazine and its derivatives [215], some of which are among the oldest. Examples include the works of Staedel-Rügheimer [216], Gutknecht [114,217], and Gastaldi [218], which are still in use today.
The reaction of α-iminocarbenoids 29 with 2H-azirines 30 delivered asymmetrically substituted pyrazines 31 in good to high yields (Scheme 12a). The authors suggest that the reaction begins with the initial formation of the metallocarbene complex of 29 with 30 to give ylide 29A, which is isomerised to 1,4-diazahexatriene 29B (Scheme 12b). Further, 1,2-dihydropyrazine formed by electrocyclisation is rapidly converted to 1,4-dihydropyrazine 29C, in which spontaneous cleavage of MeOH occurs to afford pyrazine 31. This mechanism is consistent with the observed regiochemistry of pyrazines [219].
Pyrazines can be synthesised via the dehydrogenating coupling of alcohols and amines catalysed by Ru [220], Ir [221], Co [222], Mg [223], and Pd [83] complexes. The reaction of alkynes 32 with diamine 33 under the action of divalent cobalt bromide led to a wide range of substituted pyrazines 34 (Scheme 13) [224].
The same reaction can proceed with DABCO as a catalyst, which activates sulphur to give the target products in more than 50% yields [225]. Also, a catalyst-free approach to the synthesis of pyrazine derivatives from sulfoxonium ylides and o-phenylenediamines with the participation of elemental sulphur was developed [226].
Pyrrolopyrazine derivatives have been studied for several decades [227,228]. They can be synthesised in various ways: from functionalised pyrazines or pyrroles and via a three-component reaction from acyclic compounds. Pyrrolo[1,2-a]pyrazines are also obtained by different methods, including the Pictet–Spengler reaction of isotryptamine and 2-(pyrrol-1-yl)ethanamine with trifluoromethylated carbonyl compounds and 2-perfluoroalkyl-substituted cyclic imines [229]; catalytic and thermal cycloisomerisations of propargyl-containing heterocycles [230]; and domino reaction of 2-pyrrolcarbaldehyde with vinylazides [231]. In addition, N-allylenylpyrrole-2-carbaldehydes [232,233] and N-propargylamino(pyrrolyl)enones [234] were employed as the starting compounds for the construction of such structures.
The reaction of N-propargylpyrrol-2-carbaldehyde 35 with various amines led to pyrrolo[1,2-a]pyrazines 36 (Scheme 14) [235].
A one-pot, three-component reaction between 2-methylene cyanoazaheterocycles 37, aldehyde 38, and acetylcyanide 39 afforded pyrrolo[1,2-a]pyrazine 40 (Scheme 15). The methodology involves the formation of a heterocyclic 1-aza-1,3-diene derived from a Knoevenagel condensation between an aldehyde and 2-methylene-cyano aza-heterocycles, followed by [4+1] cycloaddition of acetyl cyanide behaving as a non-classical isocyanide replacement [236].

3.2. Synthesis of Triazine Derivatives

The widespread use of triazines makes the development of efficient methods for their synthesis an important task. Methods for the preparation of 1,3,5-, 1,2,4-, and 1,2,3-triazines are described in detail below. Among the triazines described above, 1,2,3-triazines are the least studied because their ring system is considered the least stable, and their syntheses are limited.

3.2.1. Synthesis of 1,3,5-Triazine Derivatives

The synthesis of 1,3,5-triazine compounds was first reported by A. Pinner in 1890 [237]. In the syntheses of 1,3,5-triazines, triamines or polyamines were used as nucleophiles, while the substrates included aldehydes and their derivatives [238].
In 2002, Díaz-Ortiz et al. synthesised symmetrically substituted 1,3,5-triazines (30–84% yields) via the solvent-free cyclisation of nitrile reaction using Lewis acids on silicon oxide as catalysts under microwave radiation [239]. Later, this research team implemented the reaction of dicyandiamide with aromatic/aliphatic/heterocyclic nitriles under microwave irradiation in the presence of a base for 10–15 min to furnish 2,4-diamino-6-1,3,5-triazines in 52–92% yields [240]. Triazines 43 were also obtained in high yields by microwave irradiation-assisted reaction of primary aldehydes 41, which were treated with iodine in ammonia water to give the intermediate nitriles, which were subjected to [2+3] cycloaddition with dicyandiamide 42 without isolation (Scheme 16) [241].
Acid chlorides or anhydrides 44 reacted with stoichiometric amounts of zinc dimethylimidodicarbonimidate zinc 45 to form 4,6-dimethoxy-1,3,5-triazines 46 in high yields (Scheme 17) [242].
The CuI-catalysed reaction of 1,1-dibromoalkenes 47 and biguanides 48 gave rise to the substituted 2,4-diamino-1,3,5-triazines 49 (Scheme 18). The reaction tolerated alkyl-, heteroaryl-, or aryl-substituted 1,1-dibromoalkenes to afford the products in moderate to good yields [243].
The reactions of 1,2,3,5-tetrazine 50 with amidines 51 led to the formation of substituted 4,6-diphenethyl-1,3,5-triazine 52 (Scheme 19). All amidines examined, including aryl-, heteroaryl-, and alkyl amidines 51, smoothly react with tetrazine 50 at ambient temperature to provide the 1,3,5-triazines 53 in uniformly high yields [157].

3.2.2. Synthesis of 1,2,4-Triazine Derivatives

Several reviews were devoted to the synthesis of 1,2,4-triazines [244,245]. For instance, 1,2,4-triazine derivatives 55 were prepared via simple and efficient [4+2] annulation reactions of imidohydrazides 54 with ketones, aldehydes, alkynes, secondary alcohols, and alkenes (Scheme 20) [246].
The reaction of oxazolone 56 with phenylhydrazine in the presence of acetic acid and sodium acetate delivered 1,2,4-triazine 57. The lactam form 57 is thermodynamically more stable than the enolic form 58 (Scheme 21) [247].
Pyrrolotriazine 62 was synthesised from 3-iodo-1H-pyrrole-2-carbaldehyde 59, which was converted to pyrrole-2-carbonitrile 60 (Scheme 22). Electrophilic N-amination of compound 60 followed by cyclisation of the formed N-aminopyrrole 61 with triethylorthoformate gave pyrrolo[2,1-f][1,2,4]triazine 62 [248].
Pyrrolo[2,1-f][1,2,4]triazin-4-amine 64 was prepared by a two-step reaction from pyrrole 63 (Scheme 23) [249]. 64 is an important regulatory starting material in the production of the antiviral drug Remdesivir. This method is suitable for obtaining 64 in kilogram quantities.

3.2.3. Synthesis of 1,2,3-Triazine Derivatives

It was found that (Z)-4-aryl-2,4-diazido-2-alkenoates 65 underwent cyclisation under slightly alkaline conditions without transition metals or strong acids to furnish esters of 6-aryl-1,2,3-triazine-4-carboxylic acid 66 (Scheme 24) [250].
The [5+1] cycloaddition reaction of vinyl diazo compounds 67 with tert-butyl nitrites was employed for the directed synthesis of 1,2,3-triazine-1-oxides 68, which then underwent further functionalisation (Scheme 25) [251].

3.3. Synthesis of 1,2,3,4-Tetrazine Derivatives

1,2,4,5-tetrazine (s-tetrazine) is of particular interest due to its enhanced stability. The literature review revealed that 1,2,3,4- and 1,2,3,5-tetrazines have not been sufficiently investigated, and there are only a few examples of their synthesis. A selection of examples will be illustrated below.

3.3.1. Synthesis of 1,2,3,4-Tetrazine Derivatives

The development of the experimental and theoretical chemistry of 1,2,3,4-tetrazines is comprehensively covered in the review [252]. The first compound with four neighbouring nitrogen atoms in a six-membered ring was obtained in 1972 by Nelsen and Fibiger in less than 5% yield [253].
The oxidation of 1-amino-5-phenyl-1,2,3-triazolo[4,5-d]-1,2,3-triazole 69 with lead tetraacetate afforded 1,2,3,4-tetrazine 70 (Scheme 26) [254].
The conversion of diazocyclopentadienes 71 into arylazo-diazocyclopentadienes 72 was documented [255]. Such products can spontaneously transform into 2-aryltetrazines 73 via reversible electrocyclisation (Scheme 27a). The same reaction can proceed with MeLi and subsequent TsN3-associated diazoperoxide transfer to give stable products 75 (Scheme 27b).
Another approach to the formation of the 1,2,3,4-tetrazine ring 77 is shown in Scheme 28. This approach is based on the azidation of compound 76, followed by the intramolecular cyclisation of the azide group with the pyrimidinone nitrogen atom [256].

3.3.2. Synthesis of 1,2,3,5-Tetrazine Derivatives

1,2,3,5-Tetrazines are mainly obtained by the reactions of pyrazoles or triazoles with amines [157,257]. For instance, cycloaddition of aryl-N-sulfinylamines 79 to substituted triazolimides 78 gave rise to tetrasubstituted-1,2,3,5-tetrazines 80 (Scheme 29) [258].
Substituted 1,2,3,5-tetrazine 83 was prepared by a similar reaction from 1,2,3-triazole 81 and ((4-nitrophenyl)imino)-14-sulfanone 82 (Scheme 30) [259].
The synthesis can be started with the condensation of 1,2-benzisoxazole-3-hydrazine 85 with the α-diketones 84 to provide the bishydrazones 86 in near quantitative yield. A subsequent (CAN)-mediated oxidation followed by an acid promoted ring-closure reaction generated the zwitterionic N1,N2-substituted 1,2,3-triazolium intermediates 87. Conversion to the dihydro-1,2,3,5-tetrazine system 88 was accomplished through a 1,3-dipolar cycloaddition-triggered rearrangement cascade (Scheme 31).

3.3.3. Synthesis of 1,2,4,5-Tetrazine Derivatives

The most studied of the tetrazine derivatives is 1,2,4,5-tetrazine, which is the subject of several reviews [260,261]. Most publications are devoted to the synthesis of both symmetric and asymmetric 3,6-disubstituted s-tetrazines, which are assembled by classical methods via the reactions of nitriles or carbaldehydes with hydrazine [262,263]. Pinner’s synthesis plays an important role in s-tetrazine chemistry. The dihydro-s-tetrazines synthesis involves the reaction of aromatic nitrile 89 with hydrazine 90, followed by the addition of a second nitrile molecule to give dihydro-s-tetrazines 91, which are further oxidised to s-tetrazines 92 (Scheme 32) [264].
Devaraj et al. [265] reported a one-pot synthesis of s-tetrazines 95 from aliphatic nitriles 93, 94, and hydrazine using metal (Ni and Zn) triphthalates as catalysts (Scheme 33). Zinc salts gave higher yields for less active nitriles such as those that were sterically hindered or affected by electron-donating groups. On the other hand, more reactive nitriles benefited from the use of nickel salts.
The work of Ott’s team [266] is of great importance for the synthesis of s-tetrazines. This group developed a facile method for the preparation of these compounds involving the treatment of triaminoguanidine monohydrochloride 96 with 2,4-pentanedione to deliver 3,6-bis(3,5-dimethylpyrazol-1-yl)-1,2-dihydro-1,2,4,5-tetrazine 97 in 80–85% yield, followed by oxidation of 97 with nitric oxide to 3,6-bis(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine 98 (Scheme 34).
Disubstituted asymmetric aryl- or alkyltetrazines 100 were synthesised by a solid-phase method using readily available nitriles 99 [267] as the starting materials (Scheme 35). This synthetic route was compatible with different solid-phase resins and linkers and did not require metal catalysts or high temperatures.
The synthesis of 1,2,4,5-tetrazine derivatives 102 conjugated via a 1,4-phenylene linker to the 4H-1,2,4-triazole ring 101 (Scheme 36) [268] was described. This approach leads to the desired products in satisfactory yields, regardless of the nature of the substituents attached to the terminal rings, as well as the type of groups on the triazole nitrogen atom.
Neunhoeffer’s group has published works describing the synthesis of pyrrolo[1,2-b][1,2,4,5]tetrazine derivatives 106. These were obtained by cyclisation of hydrazidine hydrochloride 103 with 2,5-dimethoxy-2,5-dihydrofuran 104 and maleic anhydride 105 (Scheme 37). The aromatisation of the dihydro derivatives can be achieved through oxidation with manganese dioxide or through hydrogen halide abstraction under the action of triethylamine. Analogous cyclisation of hydrazines with 2-formylbenzoic acid gave similar products 106 [269,270,271].
Previously, we reported on the interaction of N-allylenylpyrrol-2-carbaldehydes 107 with hydrazine hydrate and substituted hydrazines, which resulted in the assembly of complex pyrrolopyrazinotetrazine ensembles 108 via the formation of aminopyrrolopyrazinium salts 109 (Scheme 38). The syntheses of similar annulated tetrazines were also described in this work [272].

4. Conclusions

The review systematises and analyses the possible applications and methods for the synthesis of polyazo six-membered aromatic cyclic frameworks. Despite the large number of examples available in the literature, it is shown that the assembly of such structures usually begins with the interaction of aldehydes, ketones, amines, and/or with molecules containing double or triple bonds with N-nucleophiles and is carried out via sequential or intramolecular cyclisation, as well as through the recycling of some nitrogen-containing heterocycles. Each of the described techniques has certain advantages and shortcomings. The latter include the fact that many reactions under consideration require expensive catalysts, long reaction times, are carried out in several stages, etc. Therefore, it is not surprising that the development of more efficient approaches to the synthesis of polyazo heterocycles is an urgent task in modern organic chemistry. Although the list of sources is not exhaustive, the analysis performed indicates that the majority of diazines, triazines, and tetrazines exist in the form of aromatic structures. At the same time, methodologies for the creation of frameworks lacking aromaticity and containing saturated and/or partially saturated polyazo heterocycles are also known. These methodologies will be discussed in the next part of the review.

Author Contributions

Writing—original draft preparation, E.A.G. and A.V.I.; writing—review and editing, E.A.G., A.V.I. and Y.Y.T. supervision, A.V.I.; project administration, Y.Y.T. All authors have read and agreed to the published version of the manuscript.

Funding

The reported study was performed within the framework of the State Assignment № 125020401307-9.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Acknowledgments

The author is grateful to the Baikal Analytical Center for Collective Uses, SB RAS.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ΔBoiling or reflux
AcAcetyl
AIDSAcquired Immune Deficiency Syndromes.
ArAryl
BnBenzyl
BocTert-butoxycarbonyl group
BuButyl
C(+)|Ni foam(–)C(+)—graphite plate (cathode), Ni foam(–)—nickel foam (cathode)
CANCeric(IV) ammonium nitrate
CRFCorticotropin releasing factor
CyCyclohexyl
DABCO1,4-Diazabicyclo [2.2.2]octane
DBUDiazabicycloundecene
DCEDichloroethane
DMFN,N-Dimethylformamide
DMSODimethyl sulfoxide
EtEthyl
FurFuryl
IBX2-Iodoxybenzoic acid
HfacacHexafluoroacetylacetonate
HFIP1,1,1,3,3,3-Hexafluoroisopropanol
HxHexyl
LiHMDSLithium bis(trimethylsilyl)amide
NISN-Iodosuccinimide
NpNaphtyl
MeMetyl
MeCNAcetonitrile
MSMolecular sieves
MWMicrowave radiation
OTfTrifluoromethanesulfonic acid
PhPhenyl
PIVABis(tert-butylcarbonyloxy)iodobenzene
PrPropyl
PyPyridinyl
TBAClO4Tetrabutylammonium perchlorate
TBSTert-butyldimethylsilyl group
TFATrifluoroacetic acid
ThThienyl
TMSTrimethylsilyl group
TolTolyl
TsToluenesulfonyl
UVUltraviolet radiation
VinVinyl

References

  1. Abida; Alam, M.T.; Asif, M. Pharmacological activities of pyridoxines and pyridazinone Derivatives: A Review on biologically active scaffold. SAR J. Pharm. Sci. 2019, 1, 16–37. [Google Scholar] [CrossRef]
  2. Liljebris, C. Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). Bioorg. Med. Chem. 2002, 10, 3197–3212. [Google Scholar] [CrossRef]
  3. Asif, M.; Alghamdi, S. A mini-review on pyridazine analogs: Chemical and pharmacological potentials. Mini Rev. Org. Chem. 2023, 20, 100–123. [Google Scholar] [CrossRef]
  4. Natarajan, R.; Anthoni Samy, H.N.; Sivaperuman, A.; Subramani, A. Structure-activity relationships of pyrimidine derivatives and their biological activity—A review. Med. Chem. 2022, 19, 10–30. [Google Scholar] [CrossRef] [PubMed]
  5. Patil, S.B. Recent medicinal approaches of novel pyrimidine analogs: A review. Heliyon 2023, 9, e16773. [Google Scholar] [CrossRef]
  6. Chen, G.-Q.; Guo, H.-Y.; Quan, Z.-S.; Shen, Q.-K.; Li, X.; Luan, T. Natural products-pyrazine hybrids: A review of developments in medicinal chemistry. Molecules 2023, 28, 7440. [Google Scholar] [CrossRef]
  7. Huigens, R.W., 3rd; Brummel, B.R.; Tenneti, S.; Garrison, A.T.; Xiao, T. Pyrazine and phenazine heterocycles: Platforms for total synthesis and drug discovery. Molecules 2022, 27, 1112. [Google Scholar] [CrossRef]
  8. Xing, L.; An, Y.; Qin, Y.; Xin, H.; Deng, T.; Meng, K.; Liu, D.; Xue, W. Design, synthesis, and antiviral activities of myricetin derivatives containing pyridazinone. New J. Chem. 2024, 48, 117–130. [Google Scholar] [CrossRef]
  9. Flefel, E.M.; Tantawy, W.A.; El-Sofany, W.I.; El-Shahat, M.; El-Sayed, A.A.; Abd-Elshafy, D.N. Synthesis of some new pyridazine derivatives for anti-HAV evaluation. Molecules 2017, 22, 148. [Google Scholar] [CrossRef]
  10. Berhe, H.G.; Birhan, Y.S.; Beshay, B.Y.; Habib, H.J.; Hymete, A.; Bekhit, A.A. Synthesis, antileishmanial, antimalarial evaluation and molecular docking study of some hydrazine-coupled pyrazole derivatives. BMC Chem. 2024, 18, 9. [Google Scholar] [CrossRef]
  11. Tupare, S.D.; Sonawale, S.B. Synthesis of some novel isoxazoline from sec 3-amino pyridazine chalcones and their antimicrobial studies. Mediterr. J. Basic Appl. Sci. MJBAS 2023, 07, 133–140. [Google Scholar] [CrossRef]
  12. Bai, X.-Q.; Li, C.-S.; Cui, M.-Y.; Song, Z.-W.; Zhou, X.-Y.; Zhang, C.; Zhao, Y.; Zhang, T.-Y.; Jiang, T.-Y. Synthesis and molecular docking studies of novel pyrimidine derivatives as potential antibacterial agents. Mol. Divers. 2020, 24, 1165–1176. [Google Scholar] [CrossRef]
  13. Zhang, J.; Peng, J.-F.; Bai, Y.-B.; Wang, P.; Wang, T.; Gao, J.-M.; Zhang, Z.-T. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives and their antifungal activities against phytopathogenic fungi in vitro. Mol. Divers. 2016, 20, 887–896. [Google Scholar] [CrossRef]
  14. Hilmy, K.M.H.; Khalifa, M.M.A.; Hawata, M.A.A.; Keshk, R.M.A.; el-Torgman, A.A. Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives as antibacterial and antifungal agents. Eur. J. Med. Chem. 2010, 45, 5243–5250. [Google Scholar] [CrossRef] [PubMed]
  15. Alatawi, F.A.; Alrefaei, A.F.; Alqahtani, A.M.; Alsoliemy, A.; Katouah, H.A.; Abumelha, H.M.; Saad, F.A.; El-Metwaly, N.M. New thiazol-pyridazine derivatives as antimicrobial and antiviral candidates: Synthesis, and application. J. Saudi Chem. Soc. 2024, 28, 101830. [Google Scholar] [CrossRef]
  16. Ganai, A.M.; Pathan, T.K.; Mohite, S.B.; Vojáčková, V.; Řezníčková, E.; Kozlanská, K.; Kryštof, V.; Govender, K.; Mokoena, S.; Merugu, S.R.; et al. Design and synthesis of novel 1,2,4-triazolo[4,3-b]pyridazine derivatives with anti-cancer activity. J. Mol. Struct. 2023, 1291, 135938. [Google Scholar] [CrossRef]
  17. Paidi, K.R.; Tatipamula, V.B.; Kolli, M.K.; Pedakotla, V.R. Benzohydrazide incorporated imidazo[1,2-b]pyridazine: Synthesis, characterization and in vitro anti-tubercular activity. Int. J. Chem. Sci. 2017, 15, 172. [Google Scholar]
  18. Almehizia, A.A.; Khattab, A.E.A.; Darwish, A.M.; Al-Omar, M.A.; Naglah, A.M.; Bhat, M.A.; Kalmouch, A. Anti-inflammatory activity of novel derivatives of pyrazolo [3,4-d] pyridazine against digestive system inflammation. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2023, 396, 2729–2739. [Google Scholar] [CrossRef]
  19. Kandile, N.G.; Zaky, H.T. New pyrano[2,3-c]pyridazine derivatives with antimicrobial activity synthesized using piperidine as the organocatalyst. J. Enzym. Inhib. Med. Chem. 2015, 30, 44–51. [Google Scholar] [CrossRef] [PubMed]
  20. Mohamed, M.S.; Awad, S.M.; Sayed, A.I. Synthesis of certain pyrimidine derivatives as antimicrobial agents and anti-inflammatory agents. Molecules 2010, 15, 1882–1890. [Google Scholar] [CrossRef] [PubMed]
  21. Sönmez, M.; Berber, I.; Akbaş, E. Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. Eur. J. Med. Chem. 2006, 41, 101–105. [Google Scholar] [CrossRef]
  22. Rathish, I.G.; Javed, K.; Bano, S.; Ahmad, S.; Alam, M.S.; Pillai, K.K. Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives. Eur. J. Med. Chem. 2009, 44, 2673–2678. [Google Scholar] [CrossRef]
  23. Alghamdi, S.; Asif, M. Role of pyridazine analogs as acetylcholinesterase inhibitor: An approach for management of alzheimer’s disease. Eurasian Chem. Commun. 2021, 3, 435–442. [Google Scholar] [CrossRef]
  24. Khalil, N.A.; Ahmed, E.M.; Mohamed, K.O.; Nissan, Y.M.; Zaitone, S.A.-B. Synthesis and biological evaluation of new pyrazolone-pyridazine conjugates as anti-inflammatory and analgesic agents. Bioorg. Med. Chem. 2014, 22, 2080–2089. [Google Scholar] [CrossRef]
  25. Asif, M.; Imran, M. Antitubercular and Anticonvulsant Activities of Phenyl-di-hydropyridazinone Derivatives Containing 2-Substituted amin-1-yl-methyl and 2-(2-1H-amin-1-yl) ethyl Moieties. Anal. Chem. Lett. 2020, 10, 414–427. [Google Scholar] [CrossRef]
  26. Asif, M.; Allahyani, M.; Almehmadi, M.M.; Alsaiari, A.A. Applications and biological potential of substituted pyridazine analogs in medicinal and agricultural fields. Curr. Org. Chem. 2023, 27, 814–820. [Google Scholar] [CrossRef]
  27. Tucaliuc, R.A.; Mangalagiu, V.; Mangalagiu, I.I. Pyridazinic bioisosteres with potential applications in medicinal chemistry and agriculture. Processes 2023, 11, 2306. [Google Scholar] [CrossRef]
  28. Mohd, I.; Mohammad, A. Study of Various Pyridazine and Phthalazine Drugs with Diverse Therapeutical and Agrochemical Activities. Russ. J. Bioorg. Chem. 2020, 46, 745–767. [Google Scholar] [CrossRef]
  29. Food Safety Commission of Japan. Pyridachlometyl (pesticides). Food Saf. 2023, 11, 21–24. [Google Scholar] [CrossRef]
  30. Ovchinnikov, A.; Yu, N.A.M.; Dzhimsheleishvili, N.P.; Nikolaeva, Y.O. Principles of modern pharmacotherapy of allergic rhinitis: Efficiency, safety, reliability. Eff. Pharmacother. 2022, 1, 16–22. [Google Scholar] [CrossRef]
  31. Kao, Y.-H.; Cheng, C.-C.; Chen, Y.-C.; Chung, C.-C.; Lee, T.-I.; Chen, S.-A.; Chen, Y.-J. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes. Lab. Investig. 2011, 91, 1291–1297. [Google Scholar] [CrossRef]
  32. Talitsky, K.A.; Bulkina, O.S. Adelfan-Ezidrex as an effective combination drug for the treatment of arterial hypertension: An unbiased view. Russ. Med. J. 2005, 19, 1250. [Google Scholar]
  33. Ohno, K.; Arima, K.; Tanaka, S.; Yamagata, T.; Tsurugi, H.; Mashima, K. Synthesis and Characterization of Proximal Dinuclear Complexes of Palladium Supported by 2,6-Bis (arylimino) phenoxy (aryl-2,6-diisopropylphenyl and 2,4,6-tri-tert-butylphenyl) and 3,6-Bis(imino (2, 6-diisopropylphenyl)) pyridazine Ligands. Organometallics 2009, 28, 3256–3263. [Google Scholar] [CrossRef]
  34. Szymczak, N.K.; Berben, L.A.; Peters, J.C. Redox rich dicobalt macrocycles as templates for multi-electron transformations. Chem. Commun. 2009, 2009, 6729–6731. [Google Scholar] [CrossRef]
  35. Wriedt, M.; Näther, C. Dimorphic Modification of the Trinuclear Nickel(II) Complex [Ni3(NCS)6(pdz)6]: Synthesis, Crystal Structure, Thermal, Magnetic and Spectroscopic Properties. Z. Anorg. Allg. Chem. 2009, 635, 2459–2464. [Google Scholar] [CrossRef]
  36. Krotkus, S.; Matulaitis, T.; Diesing, S.; Copley, G.; Archer, E.; Keum, C.; Cordes, D.B.; Slawin, A.M.Z.; Gather, M.C.; Zysman-Colman, E.; et al. Fast delayed emission in new pyridazine-based compounds. Front. Chem. 2020, 8, 572862. [Google Scholar] [CrossRef]
  37. Chmovzh, T.N.; Knyazeva, E.A.; Tanaka, E.; Popov, V.V.; Mikhalchenko, L.V.; Robertson, N.; Rakitin, O.A. [1,2,5]thiadiazolo[3,4-d]pyridazine as an internal acceptor in the D-A-π-A organic sensitizers for dye-sensitized solar cells. Molecules 2019, 24, 1588. [Google Scholar] [CrossRef]
  38. Zbancioc, G.N.; Mangalagiu, I.I. Microwave-Assisted Synthesis of Highly Fluorescent Pyrrolopyridazine Derivatives. Synlett 2006, 2006, 0804–0806. [Google Scholar] [CrossRef]
  39. Zbancioc, G.; Mangalagiu, I.I. Pyrrolopyridazine derivatives as blue organic luminophores: Synthesis and properties. Part 2. Tetrahedron 2010, 66, 278–282. [Google Scholar] [CrossRef]
  40. Zbancioc, G.N.; Huhn, T.; Groth, U.; Deleanu, C.; Mangalagiu, I.I. Pyrrolodiazine derivatives as blue organic luminophores: Synthesis and properties. Part 3. Tetrahedron 2010, 66, 4298–4306. [Google Scholar] [CrossRef]
  41. Maftei, D.; Zbancioc, G.; Humelnicu, I.; Mangalagiu, I. Conformational effects on the lowest excited states of benzoyl-pyrrolopyridazine: Insights from PCM time-dependent DFT. J. Phys. Chem. A. 2013, 117, 3165–3175. [Google Scholar] [CrossRef]
  42. Moldoveanu, C.; Amariucai-Mantu, D.; Mangalagiu, V. Microwave Assisted Reactions of Fluorescent Pyrrolodiazine Building Blocks. Molecules 2019, 24, 3760. [Google Scholar] [CrossRef]
  43. Slagman, S.; Fessner, W.-D. Biocatalytic routes to anti-viral agents and their synthetic intermediates. Chem. Soc. Rev. 2021, 50, 1968–2009. [Google Scholar] [CrossRef]
  44. Khatavi, S.Y.; Kamanna, K. Facile and greener method synthesis of pyrano[2,3-d]pyrimidine-2,4,7-triones: Electrochemical and biological activity evaluation studies. J. Mol. Struct. 2022, 1250, 131708. [Google Scholar] [CrossRef]
  45. Ferazoddin, M.; Marupati, S.; Dasari, G.; Syeda, A.B.; Ali, M.I.; Manchal, R.; Bokkala, K.; Bandari, S. New quinoxaline-piperazine-oxazole conjugates: Synthesis, in vitro anticancer, in silico ADMET, and molecular docking studies. J. Heterocycl. Chem. 2024, 61, 627–641. [Google Scholar] [CrossRef]
  46. El-Gaby, M.S.A.; Gaber, A.M.; Atalla, A.A.; Abd Al-Wahab, K.A. Novel synthesis and antifungal activity of pyrrole and pyrrolo[2,3-d]pyrimidine derivatives containing sulfonamido moieties. Farmaco 2002, 57, 613–617. [Google Scholar] [CrossRef]
  47. Kaur, R.; Chaudhary, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. Eur. J. Med. Chem. 2017, 132, 108–134. [Google Scholar] [CrossRef]
  48. Bassyouni, F.; Tarek, M.; Salama, A.; Ibrahim, B.; Salah El Dine, S.; Yassin, N.; Hassanein, A.; Moharam, M.; Abdel-Rehim, M. Promising antidiabetic and antimicrobial agents based on fused pyrimidine derivatives: Molecular modeling and biological evaluation with histopathological effect. Molecules 2021, 26, 2370. [Google Scholar] [CrossRef]
  49. Poletto, J.; da Silva, M.J.V.; Jacomini, A.P.; Bidóia, D.L.; Volpato, H.; Nakamura, C.V.; Rosa, F.A. Antiparasitic activities of novel pyrimidine N-acylhydrazone hybrids. Drug Dev. Res. 2021, 82, 230–240. [Google Scholar] [CrossRef]
  50. Sirakanyan, S.N.; Spinelli, D.; Geronikaki, A.; Kartsev, V.; Hakobyan, E.K.; Petrou, A.; Paronikyan, R.G.; Nazaryan, I.M.; Akopyan, H.H.; Hovakimyan, A.A. Synthesis and neurotropic activity of new heterocyclic systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and pyridofuro[3′,2′:4,5]pyrimido[1,2-a]azepines. Molecules 2021, 26, 3320. [Google Scholar] [CrossRef]
  51. Chauhan, M.; Kumar, R. Medicinal attributes of pyrazolo[3,4-d]pyrimidines: A review. Bioorg. Med. Chem. 2013, 21, 5657–5668. [Google Scholar] [CrossRef] [PubMed]
  52. Singh, K.; Pal, R.; Khan, S.A.; Kumar, B.; Akhtar, M.J. Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. J. Mol. Struct. 2021, 1237, 130369. [Google Scholar] [CrossRef]
  53. Abdel-Aziz, S.A.; Taher, E.S.; Lan, P.; El-Koussi, N.A.; Salem, O.I.A.; Gomaa, H.A.M.; Youssif, B.G.M. New pyrimidine/thiazole hybrids endowed with analgesic, anti-inflammatory, and lower cardiotoxic activities: Design, synthesis, and COX-2/sEH dual inhibition. Arch. Pharm. 2022, 355, e2200024. [Google Scholar] [CrossRef]
  54. Kazantseva, I.A. Clinical efficacy of acyclovir and valtresc in the treatment of recurrent herpes labialis in children. Educ. Bull. Conscious. 2006, 8, 326–327. [Google Scholar]
  55. Kłysik, K.; Pietraszek, A.; Karewicz, A.; Nowakowska, M. Acyclovir in the treatment of herpes viruses—A review. Curr. Med. Chem. 2020, 27, 4118–4137. [Google Scholar] [CrossRef]
  56. De Clercq, E. Fifty years in search of selective antiviral drugs. J. Med. Chem. 2019, 62, 7322–7339. [Google Scholar] [CrossRef]
  57. Lamb, Y.N. Rosuvastatin/ezetimibe: A review in hypercholesterolemia. Am. J. Cardiovasc. Drugs 2020, 20, 381–392. [Google Scholar] [CrossRef]
  58. Qazi, S.U.; Qamar, U.; Maqsood, M.T.; Gul, R.; Ansari, S.A.; Imtiaz, Z.; Noor, A.; Suheb, M.Z.K.; Zaheer, Z.; Andleeb, A.; et al. Efficacy of allopurinol in improving endothelial dysfunction: A systematic review and meta-analysis. High Blood Press. Cardiovasc. Prev. 2023, 30, 539–550. [Google Scholar] [CrossRef]
  59. Stojkovic, M.; Radmanovic, B.; Jovanovic, M.; Janjic, V.; Muric, N.; Ristic, D.I. Risperidone induced hyperprolactinemia: From basic to clinical studies. Front. Psychiatry 2022, 13, 874705. [Google Scholar] [CrossRef]
  60. Tefferi, A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N. Engl. J. Med. 2012, 366, 844–846. [Google Scholar] [CrossRef]
  61. Samson, K. One cord blood unit effective, safer than two in younger leukemia patients. Oncol. Times 2014, 36, 39–40. [Google Scholar] [CrossRef]
  62. Kenmotsu, H.; Yamamoto, N.; Yamanaka, T.; Yoshiya, K.; Takahashi, T.; Ueno, T.; Goto, K.; Daga, H.; Ikeda, N.; Sugio, K.; et al. Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2020, 38, 2187–2196. [Google Scholar] [CrossRef]
  63. Rossi, A.; Ricciardi, S.; Maione, P.; de Marinis, F.; Gridelli, C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009, 66, 141–149. [Google Scholar] [CrossRef]
  64. Nishimura, S.; Harada, F.; Ikehara, M. The selective utilization of tubercidin triphosphate as an ATP analog in the DNA-dependent RNA polymerase system. Acta Biochim. Biophys. Sin. 1966, 129, 301–309. [Google Scholar] [CrossRef]
  65. Cohen, M.B.; Glazer, R.I. Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells. Mol. Pharmacol. 1985, 27, 349–355. [Google Scholar] [CrossRef]
  66. Renau, T.E.; Lee, J.S.; Kim, H.; Young, C.G.; Wotring, L.L.; Townsend, L.B.; Drach, J.C. Relationship between cytotoxicity and conversion of thiosangivamycin analogs to toyocamycin analogs in cell culture medium. Biochem. Pharmacol. 1994, 48, 801–807. [Google Scholar] [CrossRef] [PubMed]
  67. Robins, R.K.; Revankar, G.R. Purine analogs and related nucleosides and nucleotides as antitumor agents. Med. Res. Rev. 1985, 5, 273–296. [Google Scholar] [CrossRef] [PubMed]
  68. Cousins, D.L.; Fricero, P.; Kopf, K.P.M.; McColl, E.J.; Czechtizky, W.; Lim, Y.H.; Harrity, J.P.A. Pyrimidin-6-yl Trifluoroborate Salts as Versatile Templates for Heterocycle Synthesis. Angew. Chem. Int. Ed. 2021, 60, 9412–9415. [Google Scholar] [CrossRef]
  69. Fischer, T.; Bamberger, J.; Mancheño, O.G. Asymmetric nucleophilic dearomatization of diazarenes by anion-binding catalysis. Org. Biomol. Chem. 2016, 14, 5794–5802. [Google Scholar] [CrossRef]
  70. Resch, V.; Seidler, C.; Chen, B.S.; Degeling, I.; Hanefeld, U. On the Michael Addition of Water to α,β-Unsaturated Ketones Using Amino Acids. Eur. J. Org. Chem. 2013, 2013, 7697–7704. [Google Scholar] [CrossRef]
  71. George, J.T.; Srivatsan, S.G. Bioorthogonal chemistry-based RNA labeling technologies: Evolution and current state. Chem. Commun. 2020, 56, 12307–12318. [Google Scholar] [CrossRef]
  72. Evers, W.J.; Matawan, J.S. Flavoring with an Oxocyclic Pyrimidine. US Patent 3857972, 31 December 1974. [Google Scholar]
  73. Chen, Y.-K.; Kuo, H.-H.; Luo, D.; Lai, Y.-N.; Li, W.-C.; Chang, C.-H.; Escudero, D.; Jen, A.K.Y.; Hsu, L.-Y.; Chi, Y. Phenyl- and Pyrazolyl-Functionalized Pyrimidine: Versatile Chromophore of Bis-Tridentate Ir(III) Phosphors for Organic Light-Emitting Diodes. Chem. Mater. 2019, 31, 6453–6464. [Google Scholar] [CrossRef]
  74. Navarro, J.A.R.; Barea, E.; Galindo, M.A.; Salas, J.M.; Romero, M.A.; Quirós, M.; Masciocchi, N.; Galli, S.; Sironi, A.; Lippert, B. Soft functional polynuclear coordination compounds containing pyrimidine bridges. J. Solid. State Chem. 2005, 178, 2436–2451. [Google Scholar] [CrossRef]
  75. Achelle, S.; Nouira, I.; Pfaffinger, B.; Ramondenc, Y.; Plé, N.; Rodríguez-López, J. V-Shaped 4,6-Bis(arylvinyl)pyrimidine Oligomers: Synthesis and Optical Properties. J. Org. Chem. 2009, 74, 3711–3717. [Google Scholar] [CrossRef]
  76. Patra, A.; Ralston, J.; Sedev, R.; Zhou, J. Design of Pyrimidine-Based Photoresponsive Surfaces and Light-Regulated Wettability. Langmuir 2009, 25, 11486–11494. [Google Scholar] [CrossRef]
  77. Meyer, D.; Taige, M.A.; Zeller, A.; Hohlfeld, K.; Ahrens, S.; Strassner, T. Palladium complexes with pyrimidine-functionalized N-heterocyclic carbene ligands: Synthesis, structure and catalytic activity. Organomet. Chem. 2009, 28, 2142–2149. [Google Scholar] [CrossRef]
  78. Saito, R.; Tokita, M.; Uda, K.; Ishikawa, C.; Satoh, M. Synthesis and in vitro evaluation of botryllazine B analogues as a new class of inhibitor against human aldose reductase. Tetrahedron 2009, 65, 3019–3026. [Google Scholar] [CrossRef]
  79. Taylor, E.C.; Perlman, K.L.; Sword, I.P.; Sequin-Frey, M.; Jacobi, P.A. Pteridines. XXVIII. New, general, and unequivocal pterin synthesis. J. Am. Chem. Soc. 1973, 95, 6407–6412. [Google Scholar] [CrossRef]
  80. Janssens, T.K.S.; Tyc, O.; Besselink, H.; de Boer, W.; Garbeva, P. Biological activities associated with the volatile compound 2,5-bis(1-methylethyl)-pyrazine. FEMS Microbiol. Lett. 2019, 366, fnz023. [Google Scholar] [CrossRef]
  81. Dickschat, J.S.; Reichenbach, H.; Wagner-Döbler, I.; Schulz, S. Novel Pyrazines from the Myxobacterium Chondromyces crocatus and Marine Bacteria. Eur. J. Org. Chem. 2005, 2005, 4141–4153. [Google Scholar] [CrossRef]
  82. Jeong, J.U.; Sutton, S.C.; Kim, S.; Fuchs, P.L. Biomimetic total syntheses of (+)-cephalostatin 7, (+)-cephalostatin 12, and (+)-ritterazine K. J. Am. Chem. Soc. 1995, 117, 10157–10158. [Google Scholar] [CrossRef]
  83. Chaignaud, M.; Gillaizeau, I.; Ouhamou, N.; Coudert, G. New highlights in the synthesis and reactivity of 1,4-dihydropyrazine derivatives. Tetrahedron 2008, 64, 8059–8066. [Google Scholar] [CrossRef]
  84. Wang, Y.-T.; Yang, P.-C.; Zhang, J.-Y.; Sun, J.-F. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy. Molecules 2024, 29, 1448. [Google Scholar] [CrossRef]
  85. Yang, Y.; Zhu, Q.; Zhong, Y.; Cui, X.; Jiang, Z.; Wu, P.; Zheng, X.; Zhang, K.; Zhao, S. Synthesis, anti-microbial and anti-inflammatory activities of 18β-glycyrrhetinic acid derivatives. Bioorg. Chem. 2020, 101, 103985. [Google Scholar] [CrossRef]
  86. Müller, R.; Rappert, S. Pyrazines: Occurrence, formation and biodegradation. Appl. Microbiol. Biotechnol. 2010, 85, 1315–1320. [Google Scholar] [CrossRef]
  87. Green, J.B.; Bethel, M.A.; Armstrong, P.W.; Buse, J.B.; Engel, S.S.; Garg, J.; Josse, R.; Kaufman, K.D.; Koglin, J.; Korn, S.; et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015, 373, 232–242. [Google Scholar] [CrossRef]
  88. Haddy, F.J.; Pamnani, M.B.; Swindall, B.T.; Johnston, J.; Cragoe, E.J. Sodium channel blockers are vasodilator as well as natriuretic and diuretic agents. Hypertension 1985, 7, I121–I126. [Google Scholar] [CrossRef]
  89. Helzlsouer, K.J.; Kensler, T.W. Cancer chemoprotection by oltipraz: Experimental and clinical considerations. Prev. Med. 1993, 22, 783–795. [Google Scholar] [CrossRef]
  90. Ala, M.; Mohammad Jafari, R.; Dehpour, A.R. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. Fundam. Clin. Pharmacol. 2021, 35, 235–259. [Google Scholar] [CrossRef]
  91. Sanders, O. Sildenafil for the treatment of Alzheimer’s disease: A systematic review. J. Alzheimers Dis. 2020, 4, 91–106. [Google Scholar] [CrossRef]
  92. Park, M.S.; Kim, B.-R.; Dong, S.M.; Lee, S.-H.; Kim, D.-Y.; Rho, S.B. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Oncotarget 2014, 5, 4935–4944. [Google Scholar] [CrossRef]
  93. Ghimire, S.; Van’t Boveneind-Vrubleuskaya, N.; Akkerman, O.W.; de Lange, W.C.; van Soolingen, D.; Kosterink, J.G.; van der Werf, T.S.; Wilffert, B.; Touw, D.J.; Alffenaar, J.W. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. J. Antimicrob. Chemother. 2016, 71, 2691–2703. [Google Scholar] [CrossRef]
  94. Liou, J.-M.; Jiang, X.-T.; Chen, C.-C.; Luo, J.-C.; Bair, M.-J.; Chen, P.-Y.; Chou, C.-K.; Fang, Y.-J.; Chen, M.-J.; Chen, C.-C.; et al. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: A multicentre, open-label, randomised controlled trial. Lancet Gastroenterol. Hepatol. 2023, 8, 228–241. [Google Scholar] [CrossRef]
  95. Kanth, S.; Malgar Puttaiahgowda, Y.; Gupta, S.; Swathi, T. Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers. J. Biomater. Sci. Polym. Ed. 2023, 34, 918–949. [Google Scholar] [CrossRef]
  96. Zusso, M.; Lunardi, V.; Franceschini, D.; Pagetta, A.; Lo, R.; Stifani, S.; Frigo, A.C.; Giusti, P.; Moro, S. Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J. Neuroinflamm. 2019, 16, 148. [Google Scholar] [CrossRef]
  97. Van Tyle, J.H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 1984, 4, 343–373. [Google Scholar] [CrossRef]
  98. Wichniak, A.; Wierzbicka, A.E.; Jarema, M. Treatment of insomnia—effect of trazodone and hypnotics on sleep. Psychiatr. Pol. 2021, 55, 743–755. [Google Scholar] [CrossRef]
  99. Geoffroy, P.A.; Lejoyeux, M.; Rolland, B. Management of insomnia in alcohol use disorder. Expert Opin. Pharmacother. 2020, 21, 297–306. [Google Scholar] [CrossRef]
  100. Cox, J.H.; Cavanna, A.E. Aripiprazole for the treatment of Tourette syndrome. Expert Rev. Neurother. 2021, 21, 381–391. [Google Scholar] [CrossRef]
  101. Pozderac, I.; Lugović-Mihić, L.; Artuković, M.; Stipić-Marković, A.; Kuna, M.; Ferček, I. Chronic inducible urticaria: Classification and prominent features of physical and non-physical types. Acta Dermatovenerol. Alp. Pannonica Adriat. 2020, 29, 141–148. [Google Scholar] [CrossRef]
  102. Ferreri, M.; Hantouche, E.G. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr. Scand. Suppl. 1998, 393, 102–108. [Google Scholar] [CrossRef]
  103. Louzada, L.L.; Machado, F.V.; Nóbrega, O.T.; Camargos, E.F. Zopiclone to treat insomnia in older adults: A systematic review. Eur. Neuropsychopharmacol. 2021, 50, 75–92. [Google Scholar] [CrossRef] [PubMed]
  104. von Brevern, M.; Lempert, T. Vestibular migraine: Treatment and prognosis. Semin. Neurol. 2020, 40, 83–86. [Google Scholar] [CrossRef]
  105. Edwards, C.A.; Thompson, A.R. Pesticides and the soil fauna. Residue Rev. 1973, 45, 1–79. [Google Scholar] [CrossRef]
  106. Ren, A.; Zhang, Y.; Bian, Y.; Liu, Y.-J.; Zhang, Y.-X.; Ren, C.-J.; Zhou, Y.; Zhang, T.; Feng, X.-S. Pyrazines in food samples: Recent update on occurrence, formation, sampling, pretreatment and analysis methods. Food Chem. 2024, 430, 137086. [Google Scholar] [CrossRef]
  107. Velusamy, M.; Huang, J.-H.; Hsu, Y.-C.; Chou, H.-H.; Ho, K.-C.; Wu, P.-L.; Chang, W.-H.; Lin, J.T.; Chu, C.-W. Dibenzo[f,h]thieno[3,4-b]quinoxaline-Based Small Molecules for Efficient Bulk-Heterojunction Solar Cells. Org. Lett. 2009, 11, 4898–4901. [Google Scholar] [CrossRef] [PubMed]
  108. Mastalerz, M.; Fischer, V.; Ma, C.-Q.; Janssen, R.A.J.; Bäuerle, P. Conjugated oligothienyl dendrimers based on a pyrazino[2,3-g]quinoxaline core. Org. Lett. 2009, 11, 4500–4503. [Google Scholar] [CrossRef]
  109. Zhang, C.Y.; Tour, J.M. Synthesis of highly functionalized pyrazines by ortho-lithiation reactions. Pyrazine ladder polymers. J. Am. Chem. Soc. 1999, 121, 8783–8790. [Google Scholar] [CrossRef]
  110. Ocheje, M.U.; Goodman, R.B.; Onge, P.B.J.S.; Malik, M.-N.; Yadiki, M.; He, Y.; Tao, Y.; Chu, T.-Y.; Rondeau-Gagné, S. Pyrazine as a noncovalent conformational lock in semiconducting polymers for enhanced charge transport and stability in thin film transistors. J. Mater. Chem. C Mater. Opt. Electron. Devices 2019, 7, 11507–11514. [Google Scholar] [CrossRef]
  111. Ma, S.; Wang, J.; Feng, K.; Zhang, H.; Wu, Z.; Wang, Y.; Liu, B.; Li, Y.; An, M.; Gonzalez-Nuñez, R.; et al. N-type polymer semiconductors based on dithienylpyrazinediimide. ACS Appl. Mater. Interfaces 2023, 15, 1639–1651. [Google Scholar] [CrossRef]
  112. Li, C.; Wang, Y.; Yin, Y.; Li, Y.; Li, J.; Sun, D.; Lu, J.; Zhang, G.; Sun, R. A comprehensive study of pyrazine-contained and low-temperature curable polyimide. Polymer 2021, 228, 123963. [Google Scholar] [CrossRef]
  113. Wang, H.; Wen, Y.; Yang, X.; Wang, Y.; Zhou, W.; Zhang, S.; Zhan, X.; Liu, Y.; Shuai, Z.; Zhu, D. Fused-ring pyrazine derivatives for n-type field-effect transistors. ACS Appl. Mater. Interfaces 2009, 1, 1122–1129. [Google Scholar] [CrossRef]
  114. dos Santos, P.L.; Chen, D.; Rajamalli, P.; Matulaitis, T.; Cordes, D.B.; Slawin, A.M.Z.; Jacquemin, D.; Zysman-Colman, E.; Samuel, I.D.W. Use of pyrimidine and pyrazine bridges as a design strategy to improve the performance of thermally activated delayed fluorescence organic light emitting diodes. ACS Appl. Mater. Interfaces 2019, 11, 45171–45179. [Google Scholar] [CrossRef]
  115. Chen, D.; Zhang, L.; Matulaitis, T.; Cordes, D.B.; Slawin, A.M.Z.; Zhang, X.-H.; Samuel, I.D.W.; Zysman-Colman, E. Tuning the emission and exciton utilization mechanisms of pyrazine-based multi-carbazole emitters and their use in organic light-emitting diodes. J. Mater. Chem. C Mater. Opt. Electron. Devices 2023, 11, 13095–13105. [Google Scholar] [CrossRef]
  116. Shahari, M.S.B.; Dolzhenko, A.V. A closer look at N2,6-substituted 1,3,5-triazine-2,4-diamines: Advances in synthesis and biological activities. Eur. J. Med. Chem. 2022, 241, 114645. [Google Scholar] [CrossRef]
  117. Li, F.; Wang, C.; Xu, Y.; Zhao, Z.; Su, J.; Luo, C.; Ning, Y.; Li, Z.; Li, C.; Wang, L. Efficient synthesis of unsymmetrical trisubstituted 1,3,5-triazines catalyzed by hemoglobin. J. Mol. Catal. 2021, 505, 111519. [Google Scholar] [CrossRef]
  118. Bai, L.; Wei, C.; Zhang, J.; Song, R. Design, synthesis, and anti-PVY biological activity of 1,3,5-triazine derivatives containing piperazine structure. Int. J. Mol. Sci. 2023, 24, 8280. [Google Scholar] [CrossRef]
  119. Cascioferro, S.; Parrino, B.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Diana, P.; Cirrincione, G. An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds. Eur. J. Med. Chem. 2017, 142, 328–375. [Google Scholar] [CrossRef]
  120. Abdel-Rahman, R.M.; Morsy, J.M.; Hanafy, F.; Amene, H.A. Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs: Part I. Die Pharm. 1999, 54, 347–351. [Google Scholar]
  121. Schmitz, W.D.; Brenner, A.B.; Bronson, J.J.; Ditta, J.L.; Griffin, C.R.; Li, Y.W.; Lodge, N.J.; Molski, T.F.; Olson, R.E.; Zhuo, X.; et al. 5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists. Bioorg. Med. Chem. Lett. 2010, 20, 3579–3583. [Google Scholar] [CrossRef] [PubMed]
  122. Hynes, J., Jr.; Dyckman, A.J.; Lin, S.; Wrobleski, S.T.; Wu, H.; Gillooly, K.M.; Kanner, S.B.; Lonial, H.; Loo, D.; McIntyre, K.W.; et al. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. J. Med. Chem. 2008, 51, 4–16. [Google Scholar] [CrossRef]
  123. Cascioferro, S.; Parrino, B.; Spanò, V.; Carbone, A.; Montalbano, A.; Barraja, P.; Diana, P.; Cirrincione, G. Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives. Eur. J. Med. Chem. 2017, 142, 74–86. [Google Scholar] [CrossRef]
  124. Cirrincione, G.; Almerico, A.M.; Barraja, P.; Diana, P.; Lauria, A.; Passannanti, A.; Musiu, C.; Pani, A.; Murtas, P.; Minnei, C.; et al. Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity. J. Med. Chem. 1999, 42, 2561–2568. [Google Scholar] [CrossRef]
  125. Bondock, S.; Rabie, R.; Etman, H.A.; Fadda, A.A. Synthesis and antimicrobial activity of some new heterocycles incorporating antipyrine moiety. Eur. J. Med. Chem. 2008, 43, 2122–2129. [Google Scholar] [CrossRef]
  126. Migawa, M.T.; Drach, J.C.; Townsend, L.B. Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7,8-hexaazaacenaphthylene as analogues of triciribine. J. Med. Chem. 2005, 48, 3840–3851. [Google Scholar] [CrossRef] [PubMed]
  127. Viswanatha, G.L.; Akinapally, N.; Krishnadas, N.; Rangappa, S.; Janardhanan, S. Analgesic, Anti-Inflammatory and Antiarthritic Activity of Newly Synthesized Bicyclothieno 1,2,3-Triazines. Iran. J. Pharmacol. Ther. 2011, 10, 31–38. [Google Scholar]
  128. Raffa, D.; Migliara, O.; Maggio, B.; Plescia, F.; Cascioferro, S.; Cusimano, M.G.; Tringali, G.; Cannizzaro, C.; Plescia, F. Pyrazolobenzotriazinone derivatives as COX inhibitors: Synthesis, biological activity, and molecular-modeling studies. Arch. Pharm. 2010, 343, 631–638. [Google Scholar] [CrossRef]
  129. Viswanatha, G.L.; Priyadarshini, B.J.; Krishnadas, N.; Janardhanan, S.; Rangappa, S.; Hanumanthappa, S. Synthesis and antihistaminic activity of 3H-benzo[4,5]thieno[2,3-d][1,2,3]triazin-4-ones. Saudi Pharm. J. 2012, 20, 45–52. [Google Scholar] [CrossRef]
  130. Perspicace, E.; Jouan-Hureaux, V.; Ragno, R.; Ballante, F.; Sartini, S.; La Motta, C.; Da Settimo, F.; Chen, B.; Kirsch, G.; Schneider, S.; et al. Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). Eur. J. Med. Chem. 2013, 63, 765–781. [Google Scholar] [CrossRef]
  131. Hunt, J.C.A.; Briggs, E.; Clarke, E.D.; Whittingham, W.G. Synthesis and SAR studies of novel antifungal 1,2,3-triazines. Bioorg. Med. Chem. Lett. 2007, 17, 5222–5226. [Google Scholar] [CrossRef]
  132. Keldsen, N.; Havsteen, H.; Vergote, I.; Bertelsen, K.; Jakobsen, A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: A phase II study. Gynecol. Oncol. 2003, 88, 118–122. [Google Scholar] [CrossRef]
  133. Malik, I.A. Altretamine is an Effective Palliative Therapy of Patients with Recurrent Epithelial Ovarian Cancer. Jpn. J. Clin. Oncol. 2001, 31, 69–73. [Google Scholar] [CrossRef]
  134. Chan, J.K.; Loizzi, V.; Manetta, A.; Berman, M.L. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol. Oncol. 2004, 92, 368–371. [Google Scholar] [CrossRef]
  135. Damia, G.; D’Incalci, M. Clinical pharmacokinetics of altretamine. Clin. Pharmacokinet. 1995, 28, 439–448. [Google Scholar] [CrossRef]
  136. Kang, Y.-K.; Yook, J.H.; Park, Y.-K.; Lee, J.S.; Kim, Y.-W.; Kim, J.Y.; Ryu, M.-H.; Rha, S.Y.; Chung, I.J.; Kim, I.-H.; et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J. Clin. Oncol. 2021, 39, 2903–2913. [Google Scholar] [CrossRef] [PubMed]
  137. Zhang, X.; Tian, X.; Wei, Y.; Deng, H.; Ma, L.; Chen, Z. Activity and safety of tegafur, gimeracil, and oteracil potassium for nasopharyngeal carcinoma: A systematic review and meta-analysis. J. Oncol. 2021, 2021, 6690275. [Google Scholar] [CrossRef] [PubMed]
  138. Jack, G.; Doyle, L.; Palejwalla, M.M. Tretamine in the treatment of inoperable lung cancer. Lancet 1960, 275, 206–207. [Google Scholar] [CrossRef] [PubMed]
  139. Hashimoto, Y.; Kotake, K.; Watanabe, N.; Fujiwara, T.; Sakamoto, S. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst. Rev. 2021, 9, CD013575. [Google Scholar] [CrossRef]
  140. Liu, C.-H.; Peng, C.-M.; Hwang, J.-I.; Liang, P.-C.; Chen, P.-J.; Abi-Jaoudeh, N.; Giiang, L.-H.; Tyan, Y.-S. Phase I dose-escalation study of tirapazamine chemoembolization for unresectable early- and intermediate-stage hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2022, 33, 926–933.e921. [Google Scholar] [CrossRef]
  141. Sztanke, K.; Rzymowska, J.; Niemczyk, M.; Dybała, I.; Kozioł, A.E. Novel derivatives of methyl and ethyl 2-(4-oxo-8-aryl-2H-3,4,6,7-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)acetates from biologically active 1-aryl-2-hydrazinoimidazolines: Synthesis, crystal structure and antiproliferative activity. Eur. J. Med. Chem. 2006, 41, 1373–1384. [Google Scholar] [CrossRef]
  142. Thieu, T.; Sclafani, J.A.; Levy, D.V.; McLean, A.; Breslin, H.J.; Ott, G.R.; Bakale, R.P.; Dorsey, B.D. Discovery and process synthesis of novel 2,7-pyrrolo[2,1-f][1,2,4]triazines. Org. Lett. 2011, 13, 4204–4207. [Google Scholar] [CrossRef] [PubMed]
  143. Sathiyan, G.; Sakthivel, P. Synthesis and characterization of triazine linked carbazole derivatives green-light-emitting molecules. Dye. Pigment. 2017, 143, 444–454. [Google Scholar] [CrossRef]
  144. Sathiyan, G.; Venkatesan, G.; Ramasamy, S.K.; Lee, J.; Barathi, S. Recent progress in triazine-based fluorescent probes for detecting hazardous nitroaromatic compounds. J. Environ. Chem. Eng. 2024, 12, 112804. [Google Scholar] [CrossRef]
  145. Zhao, G.; Wei, G.; Yan, Z.; Guo, B.; Guang, S.; Wu, R.; Xu, H. A multiple fluorescein-based turn-on fluorophore (FHCS) identified for simultaneous determination and living imaging of toxic Al3+ and Zn2+ by improved Stokes shift. Anal. Chim. Acta 2020, 1095, 185–196. [Google Scholar] [CrossRef]
  146. Wang, Y.; Jiang, Y.; Liu, D.; Wang, Y.; Wang, G.; Hua, J. Ultrafast relaxation processes of multi-branched compounds based on 1,3,5-triazine: An investigation of the causes of a high fluorescence quantum yield after modification with perfluoroalkyl chains. J. Lumin. 2017, 190, 89–93. [Google Scholar] [CrossRef]
  147. Wang, S.; Miao, S.; Lu, Y.; Li, C.; Li, B. A C-type lectin (CTL2) mediated both humoral and cellular immunity against bacterial infection in Tribolium castaneum. Pestic. Biochem. Physiol. 2024, 201, 105852. [Google Scholar] [CrossRef]
  148. Saracoglu, N. Recent advances and applications in 1,2,4,5-tetrazine chemistry. ChemInform 2007, 38, 4199–4236. [Google Scholar] [CrossRef]
  149. Churakov, A.M.; Tartakovsky, V.A. Progress in 1,2,3,4-tetrazine chemistry. Chem. Rev. 2004, 104, 2601–2616. [Google Scholar] [CrossRef]
  150. Almerico, A.M.; Mingoia, F.; Diana, P.; Barraja, P.; Lauria, A.; Montalbano, A.; Cirrincione, G.; Dattolo, G. 1-Methyl-3H-pyrazolo[1,2-a]benzo[1,2,3,4]tetrazin-3-ones. Design, synthesis, and biological activity of new antitumor agents. J. Med. Chem. 2005, 48, 2859–2866. [Google Scholar] [CrossRef]
  151. Ratnikov, M.O.; Lipilin, D.L.; Churakov, A.M.; Strelenko, Y.A.; Tartakovsky, V.A. Release of nitrosating species in the course of reduction of benzo-1,2,3,4-tetrazine 1,3-dioxides. Org. Lett. 2002, 4, 3227–3229. [Google Scholar] [CrossRef]
  152. Koukourakis, G.V.; Kouloulias, V.; Zacharias, G.; Papadimitriou, C.; Pantelakos, P.; Maravelis, G.; Fotineas, A.; Beli, I.; Chaldeopoulos, D.; Kouvaris, J. Temozolomide with radiation therapy in high grade brain gliomas: Pharmaceuticals considerations and efficacy; a review article. Molecules 2009, 14, 1561–1577. [Google Scholar] [CrossRef]
  153. Newlands, E.S.; Stevens, M.F.; Wedge, S.R.; Wheelhouse, R.T.; Brock, C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997, 23, 35–61. [Google Scholar] [CrossRef]
  154. Bleehen, N.M.; Newlands, E.S.; Lee, S.M.; Thatcher, N.; Selby, P.; Calvert, A.H.; Rustin, G.J.; Brampton, M.; Stevens, M.F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 1995, 13, 910–913. [Google Scholar] [CrossRef] [PubMed]
  155. Newlands, E.S.; Blackledge, G.R.; Slack, J.A.; Rustin, G.J.; Smith, D.B.; Stuart, N.S.; Quarterman, C.P.; Hoffman, R.; Stevens, M.F.; Brampton, M.H.; et al. Phase I trial of temozolomide. Br. J. Cancer 1992, 65, 287–291. [Google Scholar] [CrossRef]
  156. Kaim, W. The coordination chemistry of 1,2,4,5-tetrazines. Coord. Chem. Rev. 2002, 230, 127–139. [Google Scholar] [CrossRef]
  157. Wu, Z.-C.; Boger, D.L. 1,2,3,5-tetrazines: A general synthesis, cycloaddition scope, and fundamental reactivity patterns. J. Org. Chem. 2022, 87, 16829–16846. [Google Scholar] [CrossRef] [PubMed]
  158. Talawar, M.B.; Sivabalan, R.; Senthilkumar, N.; Prabhu, G.; Asthana, S.N. Synthesis, characterization and thermal studies on furazan- and tetrazine-based high energy materials. J. Hazard. Mater. 2004, 113, 11–25. [Google Scholar] [CrossRef] [PubMed]
  159. Wu, Q.; Pan, Y.; Xia, X.; Shao, Y.; Zhu, W.; Xiao, H. Theoretic design of 1,2,3,4-tetrazine-1,3-dioxide-based high-energy density compounds with oxygen balance close to zero. Struct. Chem. 2013, 24, 1579–1590. [Google Scholar] [CrossRef]
  160. Muravyev, N.V. Thermal stability vs. energy content of compound: Thermolysis of tetrazino-tetrazine 1,3,6,8-tetraoxide (TTTO) from a broad perspective. Chem. Eng. J. 2023, 472, 145032. [Google Scholar] [CrossRef]
  161. Sauer, J.; Pabst, G.R.; Holland, U.; Kim, H.-S.; Loebbecke, S. 3,6-Bis(2H-tetrazol-5-yl)-1,2,4,5-tetrazine: A Versatile Bifunctional Building Block for the Synthesis of Linear Oligoheterocycles. Eur. J. Org. Chem. 2001, 2001, 697–706. [Google Scholar] [CrossRef]
  162. Hoogenboom, R.; Moore, B.C.; Schubert, U.S. Microwave-assisted synthesis of 3,6-di(pyridin-2-yl)pyridazines: Unexpected ketone and aldehyde cycloadditions. J. Org. Chem. 2006, 71, 4903–4909. [Google Scholar] [CrossRef]
  163. Jiang, H.; Gong, Q.; Zhang, R.; Yuan, H. Tetrazine-based metal-organic frameworks. Coord. Chem. Rev. 2024, 499, 215501. [Google Scholar] [CrossRef]
  164. Audebert, P.; Clavier, G.; Allain, C. Chapter 6.3—Triazines, Tetrazines, and Fused Ring Polyaza Systems. In Progress in Heterocyclic Chemistry; Gribble, G.W., Joule, J.A., Eds.; Elsevier: Amsterdam, The Netherlands, 2016; Volume 28, pp. 493–521. [Google Scholar]
  165. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 2014, 57, 10257–10274. [Google Scholar] [CrossRef]
  166. Coates, W.J.; Kennerley, E.A.R.; Rees, C.W.; Scriven, E.F.V. Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982–1995: The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds; Elsevier: Oxford, UK, 1996. [Google Scholar]
  167. Sergeev, P.G.; Nenajdenko, V.G. Recent advances in the chemistry of pyridazine—an important representative of six-membered nitrogen heterocycles. Russ. Chem. Rev. 2020, 89, 393–429. [Google Scholar] [CrossRef]
  168. Plieva, A.T. Methods for the synthesis of pyrrolo[1,2-b]pyridazine and pyrrolo[1,2-b]cinnoline derivatives (microreview). Chem. Heterocycl. Compd. 2019, 55, 199–201. [Google Scholar] [CrossRef]
  169. Curtius, T. 20. Hydrazide und Azide organischer Säuren I. Abhandlung. J. Prakt. Chem. 1894, 50, 275–294. [Google Scholar] [CrossRef]
  170. Sayed, G.; Hamed, A.; Meligi, G.; Boraie, W.; Shafik, M. The use of 4-(3,4-dichlorophenyl)-4-oxo-2-(4-antipyrinyl)-butanoic acid in the preparation of some new heterocyclic compounds with expected biological activity. Molecules 2003, 8, 322–332. [Google Scholar] [CrossRef]
  171. Tamayo, N.; Liao, L.; Goldberg, M.; Powers, D.; Tudor, Y.-Y.; Yu, V.; Wong, L.M.; Henkle, B.; Middleton, S.; Syed, R.; et al. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2005, 15, 2409–2413. [Google Scholar] [CrossRef] [PubMed]
  172. Gao, Q.; Zhu, Y.; Lian, M.; Liu, M.; Yuan, J.; Yin, G.; Wu, A. Unexpected C-C bond cleavage: A route to 3,6-diarylpyridazines and 6-arylpyridazin-3-ones from 1,3-dicarbonyl compounds and methyl ketones. J. Org. Chem. 2012, 77, 9865–9870. [Google Scholar] [CrossRef]
  173. El-Hameed Hassan, A.A. Heterocyclic synthesis via enaminones: Synthesis and molecular docking studies of some novel heterocyclic compounds containing sulfonamide moiety. Int. J. Org. Chem. 2014, 04, 68–81. [Google Scholar] [CrossRef]
  174. Islam, M.; Sethi, V.A. Synthesis and antiviral activity of 3-substituted phenyl-6-substituted phenyl (1,2,4) triazolo(4,3-b) pyridazin. Pharm. Chem. J. 2017, 4, 28–33. [Google Scholar]
  175. Meresz, O.; Foster-Verner, P.A. Synthesis of 3-monosubstituted s-tetrazines and their reactions with monosubstituted acetylenes. J. Chem. Soc. Chem. Commun. 1972, 950–951. [Google Scholar] [CrossRef]
  176. Sauer, J.; Heldmann, D.K. Synthesis of 3,5-disubstituted pyridazines by regioselective [4+2] cycloadditions with ethynyltributyltin and subsequent replacement of the organotin substituent. Tetrahedron 1998, 54, 4297–4312. [Google Scholar] [CrossRef]
  177. Sauer, J.; Heldmann, D.K.; Hetzenegger, J.; Krauthan, J.; Sichert, H.; Schuster, J. 1,2,4,5-tetrazine: Synthesis and reactivity in [4+2] cycloadditions. Eur. J. Org. Chem. 1998, 1998, 2885–2896. [Google Scholar] [CrossRef]
  178. Yamamoto, C.; Suzuki, M.; Yoshida, S. Pyridazine Synthesis from 1,2,4,5-Tetrazines and Alkynes in 1,1,1,3,3,3-Hexafluoro-2-propanol through the Inverse Electron Demand Diels–Alder Reaction. Bull. Chem. Soc. Jpn. 2022, 95, 1741–1746. [Google Scholar] [CrossRef]
  179. Kodama, T.; Sasaki, I.; Sugimura, H. Synthesis of pyridazine derivatives via Aza-Diels-Alder reactions of 1,2,3-triazine derivatives and 1-propynylamines. J. Org. Chem. 2021, 86, 8926–8932. [Google Scholar] [CrossRef]
  180. Ghozlan, S.A.S.; Abdelhamid, I.A.; Hassaneen, H.M.; Elnagdi, M.H. Studies with enamines and azaenamines: A novel efficient route to 6-amino-1,4-dihydropyridazines and their condensed derivatives. J. Heterocycl. Chem. 2007, 44, 105–108. [Google Scholar] [CrossRef]
  181. Aziz, S.I.; Anwar, H.F.; El-Apasery, M.A.; Elnagdi, M.H. Studies with pyridazines and condensed pyridazines: Routes for synthesis of 3-amino-5-aryl-2,5-dihydro-pyridazine, 10aH-pyridazino[1,6-a]quinazoline and thieno[3,4-d]pyridazinone. J. Heterocycl. Chem. 2007, 44, 877–881. [Google Scholar] [CrossRef]
  182. Wu, Q.; Shao, P.-L.; He, Y. Synthesis of 1,4,5,6-tetrahydropyridazines and pyridazines via transition-metal-free (4 + 2) cycloaddition of alkoxyallenes with 1,2-diaza-1,3-dienes. RSC Adv. 2019, 9, 21507–21512. [Google Scholar] [CrossRef]
  183. Liu, Z.; Lou, J.; Xiao, J. TBAI/K2S2O8-promoted [4+2] annulation of ketene N,S-acetals and N-tosylhydrazones toward pyridazines. Org. Lett. 2021, 23, 1606–1610. [Google Scholar] [CrossRef] [PubMed]
  184. Huo, H.; Runa, A.; Gong, Y. Formal [3+3] cycloaddition reactions between electron-deficient cyclopropenes and hydrazones: A route to alkyl 1,4,5,6-tetrahydropyridazine-3-carboxylates. J. Org. Chem. 2019, 84, 2093–2101. [Google Scholar] [CrossRef] [PubMed]
  185. Suleman, M.; Xie, J.; Wang, Z.; Lu, P.; Wang, Y. Base promoted three-component annulation of 4-diazoisochroman-3-imines with dimethylsulfonium ylides: Synthesis of highly functionalized isochromeno[4,3-c]pyridazines. J. Org. Chem. 2021, 86, 455–465. [Google Scholar] [CrossRef]
  186. Sheibani, H.; Esfandiarpoor, Z. Multicomponent synthesis of pyridazine and pyridazinoquinazoline derivatives in the presence of catalysts such as magnesium oxide (MgO) and 12-tungstophosphoric acid (PW). J. Heterocycl. Chem. 2011, 48, 1122–1125. [Google Scholar] [CrossRef]
  187. Bel Abed, H.; Mammoliti, O.; Bande, O.; Van Lommen, G.; Herdewijn, P. Strategy for the synthesis of pyridazine heterocycles and their derivatives. J. Org. Chem. 2013, 78, 7845–7858. [Google Scholar] [CrossRef] [PubMed]
  188. Chang, M.-Y.; Lu, Y.-J.; Cheng, Y.-C. In(OTf)3-mediated synthesis of substituted pyridazines. Tetrahedron 2015, 71, 6840–6845. [Google Scholar] [CrossRef]
  189. Hashem, H.E.; Haneen, D.S.A.; Saied, K.F.; Youssef, A.S.A. Synthesis of new annulated pyridazine derivatives and studying their antioxidant and antimicrobial activities. Synth. Commun. 2019, 49, 3169–3180. [Google Scholar] [CrossRef]
  190. Moore, J.A.; Volker, E.J.; Kopay, C.M. Heterocyclic studies. 34. Tolylsulfonyl derivatives of 2,3-dihydro-5-methyl-6-phenyl-1,2-diazepin-4-one. Rearrangement to a 1,4-dihydropyridazine. J. Org. Chem. 1971, 36, 2676–2680. [Google Scholar] [CrossRef]
  191. Gradl, S.; Köckenberger, J.; Oppl, J.; Schiller, M.; Heinrich, M.R. Synthetic Route to Phenyl Diazenes and Pyridazinium Salts from Phenylazosulfonates. J. Org. Chem. 2021, 86, 6228–6238. [Google Scholar] [CrossRef]
  192. Flitsch, W.; Krämer, U. Synthesen und reaktionen von 5-Aza-indolizinen und 5-Aza-cycl[3.2.2]azin-derivaten. Tetrahedron Lett. 1968, 9, 1479–1484. [Google Scholar] [CrossRef]
  193. Flitsch, W.; Krämer, U.; Zimmermann, H. Cyclische Verbindungen mit Heterobrückenatomen, V. Zur Chemie der 1-Amino-pyrrole. Chem. Ber. 1969, 102, 3268–3276. [Google Scholar] [CrossRef]
  194. Kuhla, D.E.; Lombardino, J.O. Pyrrolodiazines with a Bridgehead Nitrogen. In Advances in Heterocyclic Chemistry; Katritzky, A.R., Boulton, A.J., Eds.; Academic Press: Cambridge, MA, USA, 1977; Volume 21, pp. 1–63. [Google Scholar]
  195. Sagyam, R.R.; Buchikonda, R.; Pitta, J.P.; Vurimidi, H.; Padi, P.R.; Ghanta, M.R. An expedient and new synthesis of pyrrolo[1,2-b]pyridazine derivatives. Beilstein J. Org. Chem. 2009, 5, 66. [Google Scholar] [CrossRef]
  196. Xiang, H.-Y.; Chen, J.-Y.; Huan, X.-J.; Chen, Y.; Gao, Z.-B.; Ding, J.; Miao, Z.-H.; Yang, C.-H. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors. Bioorg. Med. Chem. Lett. 2021, 31, 127710. [Google Scholar] [CrossRef] [PubMed]
  197. Merugu, R.; Garimella, S.; Balla, D.; Sambaru, K. Synthesis and Biological Activities of Pyrimidines: A Review. Int. J. PharmTech Res. 2016, 8, 88–93. [Google Scholar] [CrossRef]
  198. Mahfoudh, M.; Abderrahim, R.; Leclerc, E.; Campagne, J.-M. Recent approaches to the synthesis of pyrimidine derivatives. Eur. J. Org. Chem. 2017, 2017, 2856–2865. [Google Scholar] [CrossRef]
  199. Díaz-Fernández, M.; Calvo-Losada, S.; Quirante, J.J.; Sarabia, F.; Algarra, M.; Pino-González, M.S. Catalyzed methods to synthesize pyrimidine and related heterocyclic compounds. Catalysts 2023, 13, 180. [Google Scholar] [CrossRef]
  200. Müller, T.J.; Karpov, A.S. Straightforward novel one-pot enaminone and pyrimidine syntheses by coupling-addition-cyclocondensation sequences. Synthesis 2003, 2003, 2815–2826. [Google Scholar] [CrossRef]
  201. Zhichkin, P.; Fairfax, D.J.; Eisenbeis, S.A. A general procedure for the synthesis of 2-substituted pyrimidine-5-carboxylic esters. Synthesis 2002, 2002, 720–722. [Google Scholar] [CrossRef]
  202. Liu, F.; Zhang, X.; Qian, Q.; Yang, C. A concise and efficient approach to 2,6-disubstituted 4-fluoro-pyrimidines from α-CF3 aryl ketones. Synthesis 2020, 52, 273–280. [Google Scholar] [CrossRef]
  203. Romanov, A.R.; Rulev, A.Y.; Popov, A.V.; Kondrashov, E.V.; Zinchenko, S.V. Reaction of Bromoenones with Amidines: A Simple Catalyst-Free Approach to Trifluoromethylated Pyrimidines. Synthesis 2020, 52, 1512–1522. [Google Scholar] [CrossRef]
  204. Mondal, R.; Chakraborty, G.; Guin, A.K.; Sarkar, S.; Paul, N.D. Iron-Catalyzed Alkyne-Based Multicomponent Synthesis of Pyrimidines under Air. J. Org. Chem. 2021, 86, 13186–13197. [Google Scholar] [CrossRef]
  205. Qin, Z.; Ma, Y.; Li, F. Construction of a Pyrimidine Framework through [3+2+1] Annulation of Amidines, Ketones, and N,N-Dimethylaminoethanol as One Carbon Donor. J. Org. Chem. 2021, 86, 13734–13743. [Google Scholar] [CrossRef]
  206. Sagir, H.; Rai, P.; Neha, S.; Singh, P.K.; Tiwari, S.; Siddiqui, I.R. S-Nanoparticle/SDS: An efficient and recyclable catalytic system for synthesis of substituted 4H-pyrido[1,2-a]pyrimidines in aqueous admicellar medium. RSC Adv. 2016, 6, 73924–73932. [Google Scholar] [CrossRef]
  207. Jain, K.S.; Kathiravan, M.K.; Bariwal, J.B.; Chaskar, P.K.; Tompe, S.S.; Arya, N. Novel dual use of formamide-POCl3 mixture for the efficient, one-pot synthesis of condensed 2H-pyrimidin-4-amine libraries under microwave irradiation. Synth. Commun. 2013, 43, 719–727. [Google Scholar] [CrossRef]
  208. Nguyen, T.K.; Titov, G.D.; Khoroshilova, O.V.; Kinzhalov, M.A.; Rostovskii, N.V. Light-induced one-pot synthesis of pyrimidine derivatives from vinyl azides. Org. Biomol. Chem. 2020, 18, 4971–4982. [Google Scholar] [CrossRef]
  209. Zhao, Y.; Li, R.; Zhao, Q.; Yao, J.; Miao, M. Palladium/Silver Cocatalyzed Divergent Dimerization of 2H-Azirines for Regioselective Synthesis of Tetrasubstituted Pyrroles and Pyrimidines. Org. Lett. 2023, 25, 3978–3983. [Google Scholar] [CrossRef]
  210. Reisenbauer, J.C.; Paschke, A.-S.K.; Krizic, J.; Botlik, B.B.; Finkelstein, P.; Morandi, B. Direct access to quinazolines and pyrimidines from unprotected indoles and pyrroles through nitrogen atom insertion. Org. Lett. 2023, 25, 8419–8423. [Google Scholar] [CrossRef]
  211. Dutta, J.; Ghosh, S.; Hassan, A.; De Sarkar, S. Concomitant (3+3) Annulation/Fragmentation of Triazinanes with Enamines: Electrosynthesis of Multisubstituted Dihydropyrimidines. Org. Lett. 2025, 27, 2682–2686. [Google Scholar] [CrossRef]
  212. Minguez, J.; Vaquero, J.J.; García-Navio, J.; Alvarez-Builla, J. Improved synthesis of pyrrolo[1,2-c]pyrimidine and derivatives. Tetrahedron Lett. 1996, 37, 4263–4266. [Google Scholar] [CrossRef]
  213. Alizadeh, A.; Ghasemzadeh, H.; Xiao, H.-P. A highly efficient synthesis of pyrrolo[1,2-a]pyrimidine derivatives containing 1,3-indandione skeleton. ChemistrySelect 2019, 4, 7446–7449. [Google Scholar] [CrossRef]
  214. Li, T.; Chiou, M.-F.; Li, Y.; Ye, C.; Su, M.; Xue, M.; Yuan, X.; Wang, C.; Wan, W.-M.; Li, D.; et al. Synthesis of unsymmetrically tetrasubstituted pyrroles and studies of AIEE in pyrrolo[1,2-a]pyrimidine derivatives. Chem. Sci. 2022, 13, 5667–5673. [Google Scholar] [CrossRef]
  215. Ong, K.T.; Liu, Z.-Q.; Tay, M.G. Review on the synthesis of pyrazine and its derivatives. Borneo J. Resour. Sci. Technol. BJRST 2017, 7, 60–75. [Google Scholar] [CrossRef]
  216. Staedel, W.; Rügheimer, L. Ueber die Einwirkung von Ammoniak auf Chloracetylbenzol. Ber. Dtsch. Chem. Ges. 1876, 9, 563–564. [Google Scholar] [CrossRef]
  217. Gutknecht, H. Ueber nitrosoäthylmethylketon. Ber. Dtsch. Chem. Ges. 1879, 12, 2290–2292. [Google Scholar] [CrossRef]
  218. Gastaldi, C. Sulle pirazine (On pyrazines). Gazz. Chim. Ital. 1921, 51, 233–255. [Google Scholar]
  219. Loy, N.S.Y.; Kim, S.; Park, C.-M. Synthesis of unsymmetrical pyrazines based on α-diazo oxime ethers. Org. Lett. 2015, 17, 395–397. [Google Scholar] [CrossRef]
  220. Cho, C.S.; Oh, S.G. A new ruthenium-catalyzed approach for quinoxalines from o-phenylenediamines and vicinal-diols. Tetrahedron Lett. 2006, 47, 5633–5636. [Google Scholar] [CrossRef]
  221. Hille, T.; Irrgang, T.; Kempe, R. The synthesis of benzimidazoles and quinoxalines from aromatic diamines and alcohols by iridium-catalyzed acceptorless dehydrogenative alkylation. Chem. Eur. J. 2014, 20, 5569–5572. [Google Scholar] [CrossRef]
  222. Shee, S.; Ganguli, K.; Jana, K.; Kundu, S. Cobalt complex catalyzed atom-economical synthesis of quinoxaline, quinoline and 2-alkylaminoquinoline derivatives. Chem. Commun. 2018, 54, 6883–6886. [Google Scholar] [CrossRef]
  223. Daw, P.; Kumar, A.; Espinosa-Jalapa, N.A.; Diskin-Posner, Y.; Ben-David, Y.; Milstein, D. Synthesis of pyrazines and quinoxalines via acceptorless dehydrogenative coupling routes catalyzed by manganese pincer complexes. ACS Catal. 2018, 8, 7734–7741. [Google Scholar] [CrossRef]
  224. Yang, H.-R.; Hu, Z.-Y.; Li, X.-C.; Wu, L.; Guo, X.-X. Cobalt-catalyzed effective access to quinoxalines with insights in annulation of terminal alkynes and o-phenylenediamines. Org. Lett. 2022, 24, 8392–8396. [Google Scholar] [CrossRef]
  225. Tran, T.M.C.; Lai, N.D.; Bui, T.T.T.; Mac, D.H.; Nguyen, T.T.T.; Retailleau, P.; Nguyen, T.B. DABCO-catalyzed DMSO-promoted sulfurative 1,2-diamination of phenylacetylenes with elemental sulfur and o-phenylenediamines: Access to quinoxaline-2-thiones. Org. Lett. 2023, 25, 7225–7229. [Google Scholar] [CrossRef]
  226. Chaubey, T.N.; Borpatra, P.J.; Pandey, S.K. Elemental sulfur-mediated synthesis of quinoxalines from sulfoxonium ylides. Org. Lett. 2023, 25, 5329–5332. [Google Scholar] [CrossRef]
  227. Terenin, V.I.; Kabanova, E.V.; Feoktistova, E.S. Synthesis and properties of pyrrolo[1,2-a]pyrazines (review). Chem. Heterocycl. Compd. 1991, 27, 1037–1048. [Google Scholar] [CrossRef]
  228. Dehnavi, F.; Alizadeh, S.R.; Ebrahimzadeh, M.A. Pyrrolopyrazine derivatives: Synthetic approaches and biological activities. Med. Chem. Res. 2021, 30, 1981–2006. [Google Scholar] [CrossRef]
  229. Voznesenskaia, N.G.; Shmatova, O.I.; Nenajdenko, V.G. Pictet–Spengler synthesis of perfluoroalkylated tetrahydro-γ-carbolines and tetrahydropyrrolopyrazines. Synthesis 2020, 52, 263–272. [Google Scholar] [CrossRef]
  230. Seregin, I.V.; Schammel, A.W.; Gevorgyan, V. Multisubstituted N-fused heterocycles via transition metal-catalyzed cycloisomerization protocols. Tetrahedron 2008, 64, 6876–6883. [Google Scholar] [CrossRef]
  231. Chen, W.; Hu, M.; Wu, J.; Zou, H.; Yu, Y. Domino approach for the synthesis of pyrrolo[1,2-a]pyrazine from vinyl azides. Org. Lett. 2010, 12, 3863–3865. [Google Scholar] [CrossRef]
  232. Martynovskaya, S.V.; Budaev, A.B.; Ushakov, I.A.; Borodina, T.N.; Ivanov, A.V. Solvent moisture-controlled self-assembly of fused benzoimidazopyrrolopyrazines with different ring’s interposition. Molecules 2022, 27, 2460. [Google Scholar] [CrossRef]
  233. Ivanov, A.V.; Martynovskaya, S.V.; Shcherbakova, V.S.; Ushakov, I.A.; Borodina, T.N.; Bobkov, A.S.; Vitkovskaya, N.M. Ambient access to a new family of pyrrole-fused pyrazine nitrones via 2-carbonyl-N-allenylpyrroles. Org. Chem. Front. 2020, 7, 4019–4025. [Google Scholar] [CrossRef]
  234. Trofimov, B.; Sobenina, L.; Sagitova, E.; Ushakov, I. Transition-metal-free synthesis of pyrrolo[1,2-a]pyrazines via intramolecular cyclization of N-propargyl(pyrrolyl)enaminones. Synthesis 2017, 49, 4065–4081. [Google Scholar] [CrossRef]
  235. Sari, O.; Seybek, A.F.; Kaya, S.; Menges, N.; Erdem, S.S.; Balci, M. Mechanistic insights into the reaction of N-propargylated pyrrole- and indole-carbaldehyde with ammonia, alkyl amines, and branched amines: A synthetic and theoretical investigation. Eur. J. Org. Chem. 2019, 2019, 5261–5274. [Google Scholar] [CrossRef]
  236. Martinez-Ariza, G.; Mehari, B.T.; Pinho, L.A.G.; Foley, C.; Day, K.; Jewett, J.C.; Hulme, C. Synthesis of fluorescent heterocycles via a Knoevenagel/[4 + 1]-cycloaddition cascade using acetyl cyanide. Org. Biomol. Chem. 2017, 15, 6076–6079. [Google Scholar] [CrossRef]
  237. Pinner, A. Ueber Diphenyloxykyanidin. Ber. Dtsch. Chem. Ges. 1890, 23, 2919–2922. [Google Scholar] [CrossRef]
  238. Kelarev, V.I.; Karakhanov, R.A.; Polivin, Y.N.; Remizov, A.S. Synthesis of 1,3,5-triazine derivatives on the basis of carboxylic acid imino esters (review). Chem. Heterocycl. Compd. 1992, 28, 1357–1373. [Google Scholar] [CrossRef]
  239. Díaz-Ortiz, A.; de la Hoz, A.; Moreno, A.; Sánchez-Migallón, A.; Valiente, G. Synthesis of 1,3,5-triazines in solvent-free conditions catalysed by silica-supported lewis acids. Green Chem. 2002, 4, 339–343. [Google Scholar] [CrossRef]
  240. Díaz-Ortiz, Á.; Elguero, J.; Foces-Foces, C.; de la Hoz, A.; Moreno, A.; del Carmen Mateo, M.; Sánchez-Migallón, A.; Valiente, G. Green synthesis and self-association of 2,4-diamino-1,3,5-triazine derivatives. New J. Chem. 2004, 28, 952–958. [Google Scholar] [CrossRef]
  241. Shie, J.-J.; Fang, J.-M. Microwave-assisted one-pot tandem reactions for direct conversion of primary alcohols and aldehydes to triazines and tetrazoles in aqueous media. J. Org. Chem. 2007, 72, 3141–3144. [Google Scholar] [CrossRef]
  242. Gautret, P.; Oudir, S.; Rigo, B.; Hénichart, J.-P. A convenient method for the conversion of a carboxy group into a 4,6-di-methoxy-1,3,5-triazine group: Application to N-benzylpyroglutamic acids. Synthesis 2006, 2006, 2845–2848. [Google Scholar] [CrossRef]
  243. Zhang, C.; Ban, M.-T.; Zhu, K.; Zhang, L.-Y.; Luo, Z.-Y.; Guo, S.-N.; Cui, D.-M.; Zhang, Y. Copper-catalyzed synthesis of substituted 2,4-diamino-1,3,5-triazines from 1,1-dibromoalkenes and biguanides. Org. Lett. 2017, 19, 3947–3949. [Google Scholar] [CrossRef]
  244. Arshad, M.; Khan, T.A.; Khan, M.A. 1,2,4-triazine derivatives: Synthesis and biological applications. ChemInform 2015, 46. [Google Scholar] [CrossRef]
  245. Rai, G.S.; Maru, J.J. Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: The parent moiety of antiviral drug remdesivir. Chem. Heterocycl. Compd. 2020, 56, 1517–1522. [Google Scholar] [CrossRef]
  246. Tang, D.; Wang, J.; Wu, P.; Guo, X.; Li, J.-H.; Yang, S.; Chen, B.-H. Synthesis of 1,2,4-triazine derivatives via [4+2] domino annulation reactions in one pot. RSC Adv. 2016, 6, 12514–12518. [Google Scholar] [CrossRef]
  247. Hashem, H.E.; Abo-Bakr, A.M. Synthesis of some new 1,2,4-triazine and 1,2,5-oxadiazine derivatives with antimicrobial activity. Heteroat. Chem. 2019, 2019, 2326514. [Google Scholar] [CrossRef]
  248. Ji, Z.; Dai, Y.; Abad-Zapatero, C.; Albert, D.H.; Bouska, J.J.; Glaser, K.B.; Marcotte, P.A.; Soni, N.B.; Magoc, T.J.; Stewart, K.D.; et al. Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 4528–4531. [Google Scholar] [CrossRef]
  249. Roy, S.; Yadaw, A.; Roy, S.; Sirasani, G.; Gangu, A.; Brown, J.D.; Armstrong, J.D., 3rd; Stringham, R.W.; Gupton, B.F.; Senanayake, C.H.; et al. Facile and scalable methodology for the pyrrolo[2,1-f][1,2,4]triazine of remdesivir. Org. Process Res. Dev. 2022, 26, 82–90. [Google Scholar] [CrossRef]
  250. Sugimura, H.; Takeuchi, R.; Ichikawa, S.; Nagayama, E.; Sasaki, I. Synthesis of 1,2,3-triazines using the base-mediated cyclization of (Z)-2,4-diazido-2-alkenoates. Org. Lett. 2018, 20, 3434–3437. [Google Scholar] [CrossRef]
  251. De Angelis, L.; Zheng, H.; Perz, M.T.; Arman, H.; Doyle, M.P. Intermolecular [5+1]-cycloaddition between vinyl diazo compounds and tert-butyl nitrite to 1,2,3-triazine 1-oxides and their further transformation to isoxazoles. Org. Lett. 2021, 23, 6542–6546. [Google Scholar] [CrossRef]
  252. Klenov, M.S.; Voronin, A.A.; Churakov, A.M.; Tartakovsky, V.A. Advances in the chemistry of 1,2,3,4-tetrazines. Russ. Chem. Rev. 2023, 92, RCR5089. [Google Scholar] [CrossRef]
  253. Nelsen, S.F.; Fibiger, R. 1,4-Dimethyl-1,4,5,6-tetrahydro-1,2,3,4-tetrazine. Cyclic cis-2-tetrazene. J. Am. Chem. Soc. 1972, 94, 8497–8501. [Google Scholar] [CrossRef]
  254. Kaihoh, T.; Itoh, T.; Yamaguchi, K.; Ohsawa, A. First synthesis of a 1,2,3,4-tetrazine. Chem. Commun. 1988, 1608–1609. [Google Scholar] [CrossRef]
  255. Mackert, P.J.; Hafner, K.; Nimmerfroh, N.; Banert, K. Synthesis, structure and reactivity of cyclopenta-annulated 1,2,3,4-tetrazines. Chem. Ber. 1994, 127, 1479–1488. [Google Scholar] [CrossRef]
  256. Moustafa, A.H.; Mohammed, S.M.; El-Salam, E.A.A.; El-Sayed, H.A. Synthesis and antimicrobial activity of new 3H-chromeno[2,3-d]pyrimidine derivatives. Russ. J. Gen. Chem. 2020, 90, 1566–1572. [Google Scholar] [CrossRef]
  257. Gao, Y.; Lam, Y. Synthesis of pyrazolo[5,1-d][1,2,3,5]tetrazine-4(3H)-ones. J. Comb. Chem. 2010, 12, 69–74. [Google Scholar] [CrossRef] [PubMed]
  258. Butler, R.N.; Cunningham, D.; McArdle, P.; O’Halloran, G.A. 1,2,3,5-Tetrazines and 1,2,3-triazaspiro[4.4]nonanes: Remarkable products from 1,3-dipolar cycloadditions of N-sulphinylamines with substituted triazolium imides. Chem. Commun. 1988, 3, 232–234. [Google Scholar] [CrossRef]
  259. Wu, Z.-C.; Boger, D.L. Synthesis, characterization, and cycloaddition reactivity of a monocyclic aromatic 1,2,3,5-tetrazine. J. Am. Chem. Soc. 2019, 141, 16388–16397. [Google Scholar] [CrossRef]
  260. Neunhoeffer, H. 2.21—Tetrazines and Pentazines. In Comprehensive Heterocyclic Chemistry; Katritzky, A.R., Rees, C.W., Eds.; Pergamon: Oxford, UK, 1984; pp. 531–572. [Google Scholar]
  261. Sauer, J. 6.21—1,2,4,5-Tetrazines. In Comprehensive Heterocyclic Chemistry II; Katritzky, A.R., Rees, C.W., Scriven, E.F.V., Eds.; Pergamon: Oxford, UK, 1996; pp. 901–955. [Google Scholar]
  262. Wu, H.; Devaraj, N.K. Advances in tetrazine bioorthogonal chemistry driven by the synthesis of novel tetrazines and dienophiles. Acc. Chem. Res. 2018, 51, 1249–1259. [Google Scholar] [CrossRef] [PubMed]
  263. Hu, W.X.; Rao, G.W.; Sun, Y.Q. Synthesis and antitumor activity of s-tetrazine derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 1177–1181. [Google Scholar] [CrossRef]
  264. Pinner, A. Ueber die Einwirkung von Hydrazin auf Imidoäther. Ber. Dtsch. Chem. Ges. 1893, 26, 2126–2135. [Google Scholar] [CrossRef]
  265. Yang, J.; Karver, M.R.; Li, W.; Sahu, S.; Devaraj, N.K. Metal-catalyzed one-pot synthesis of tetrazines directly from aliphatic nitriles and hydrazine. Angew. Chem. Int. Ed. 2012, 51, 5222–5225. [Google Scholar] [CrossRef]
  266. Coburn, M.D.; Buntain, G.A.; Harris, B.W.; Hiskey, M.A.; Lee, K.Y.; Ott, D.G. An improved synthesis of 3,6-diamino-1,2,4,5-tetrazine. II. From triaminoguanidine and 2,4-pentanedione. J. Heterocycl. Chem. 1991, 28, 2049–2050. [Google Scholar] [CrossRef]
  267. Alghamdi, Z.S.; Klausen, M.; Gambardella, A.; Lilienkampf, A.; Bradley, M. Solid-phase synthesis of s-tetrazines. Org. Lett. 2023, 25, 3104–3108. [Google Scholar] [CrossRef]
  268. Maj, A.; Kudelko, A.; Świątkowski, M. Synthesis and luminescent properties of s-tetrazine derivatives conjugated with the 4H-1,2,4-triazole ring. Molecules 2022, 27, 3642. [Google Scholar] [CrossRef] [PubMed]
  269. Neunhoeffer, H.; Degen, H.-J. Hydrazidine, II. Die Synthese von Pyrrolo[1,2-b]-1,2,4,5-tetrazine. Chem. Ber. 1975, 108, 3509–3517. [Google Scholar] [CrossRef]
  270. Degen, H.-J.; Haller, S.; Und, K.H.; Neunhoeffer, H. Hydrazidine, III. Synthese von 1,2,4,5-tetrazino [3,2-a]isoindolen. Chem. Ber. 1979, 112, 1981–1990. [Google Scholar] [CrossRef]
  271. Neunhoeffer, H.; Karafiat, U.; Köhler, G.; Sowa, B.; Hydrazidine, V. Synthese und Reaktionen aromatischer und aliphatischer Hydrazidine und deren N1-substituierter Derivate. Liebigs Ann. Chem. 1992, 1992, 115–126. [Google Scholar] [CrossRef]
  272. Martynovskaya, S.V.; Gyrgenova, E.A.; Ushakov, I.A.; Borodina, T.N.; Ivanov, A.V. Synthesis of Tetrazines from N-Allenylpyrrole-2-carbaldehydes and pH-Controlled Reversible Fragmentation. Org. Lett. 2024, 26, 132–136. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Six-membered heterocycles with two nitrogen atoms: (a) pyridazine, (b) pyrimidine, and (c) pyrazine.
Figure 1. Six-membered heterocycles with two nitrogen atoms: (a) pyridazine, (b) pyrimidine, and (c) pyrazine.
Molecules 30 03264 g001
Figure 2. Examples of registered medicinal products comprising a pyridazine moiety.
Figure 2. Examples of registered medicinal products comprising a pyridazine moiety.
Molecules 30 03264 g002
Figure 3. Examples of registered medicinal products comprising a pyrimidine fragment.
Figure 3. Examples of registered medicinal products comprising a pyrimidine fragment.
Molecules 30 03264 g003
Figure 4. Examples of registered medicinal products comprising a pyrazine moiety.
Figure 4. Examples of registered medicinal products comprising a pyrazine moiety.
Molecules 30 03264 g004
Figure 5. Six-membered heterocycles with three nitrogen atoms: (a) 1,3,5-triazine, (b) 1,2,4-triazine, and (c) 1,2,3-triazine.
Figure 5. Six-membered heterocycles with three nitrogen atoms: (a) 1,3,5-triazine, (b) 1,2,4-triazine, and (c) 1,2,3-triazine.
Molecules 30 03264 g005
Figure 6. Examples of registered medicinal products comprising triazine moieties.
Figure 6. Examples of registered medicinal products comprising triazine moieties.
Molecules 30 03264 g006
Figure 7. Types of six-membered heterocycles with four nitrogen atoms: (a) 1,2,3,4-tetrazine, (b) 1,2,3,5-tetrazine, and (c) 1,2,4,5-tetrazine.
Figure 7. Types of six-membered heterocycles with four nitrogen atoms: (a) 1,2,3,4-tetrazine, (b) 1,2,3,5-tetrazine, and (c) 1,2,4,5-tetrazine.
Molecules 30 03264 g007
Figure 8. Examples of registered drugs comprising tetrazine moieties.
Figure 8. Examples of registered drugs comprising tetrazine moieties.
Molecules 30 03264 g008
Scheme 1. General method for the synthesis of pyridazines [170,171,172,173,174].
Scheme 1. General method for the synthesis of pyridazines [170,171,172,173,174].
Molecules 30 03264 sch001
Scheme 2. General method for the synthesis of 4 from 3 via the Diels–Alder reaction [176,177,178].
Scheme 2. General method for the synthesis of 4 from 3 via the Diels–Alder reaction [176,177,178].
Molecules 30 03264 sch002
Scheme 3. One-pot [4+2] cyclocondensation of substituted pyridazines [188].
Scheme 3. One-pot [4+2] cyclocondensation of substituted pyridazines [188].
Molecules 30 03264 sch003
Scheme 4. Pyridazine synthesised under green chemistry conditions using microwave irradiation [189].
Scheme 4. Pyridazine synthesised under green chemistry conditions using microwave irradiation [189].
Molecules 30 03264 sch004
Scheme 5. Domino-coupling–isomerisation–condensation reaction [196].
Scheme 5. Domino-coupling–isomerisation–condensation reaction [196].
Molecules 30 03264 sch005
Scheme 6. One-pot synthesis of condensed 2H-pyrimidin-4-amine libraries under microwave irradiation [207].
Scheme 6. One-pot synthesis of condensed 2H-pyrimidin-4-amine libraries under microwave irradiation [207].
Molecules 30 03264 sch006
Scheme 7. Skeletal editing of indoles and pyrroles: (a) recyclarization of indole, and (b) recyclarization of pyrrole [210].
Scheme 7. Skeletal editing of indoles and pyrroles: (a) recyclarization of indole, and (b) recyclarization of pyrrole [210].
Molecules 30 03264 sch007
Scheme 8. Electro-oxidative formal [3+3] annulation of 1,3,5-triazinane [211].
Scheme 8. Electro-oxidative formal [3+3] annulation of 1,3,5-triazinane [211].
Molecules 30 03264 sch008
Scheme 9. Cyclocondensation pyrroles with tosylmethylisocyanide [212].
Scheme 9. Cyclocondensation pyrroles with tosylmethylisocyanide [212].
Molecules 30 03264 sch009
Scheme 10. One-pot three-component synthesis of pyrrolo[1,2-a]pyrimidine [213].
Scheme 10. One-pot three-component synthesis of pyrrolo[1,2-a]pyrimidine [213].
Molecules 30 03264 sch010
Scheme 11. Construction of multisubstituted pyrrolo[1,2-a]pyrimidines [214].
Scheme 11. Construction of multisubstituted pyrrolo[1,2-a]pyrimidines [214].
Molecules 30 03264 sch011
Scheme 12. (a) Cu-catalyzed synthesis and proposed mechanism of unsymmetrical pyrazines, and (b) proposed mechanism [219].
Scheme 12. (a) Cu-catalyzed synthesis and proposed mechanism of unsymmetrical pyrazines, and (b) proposed mechanism [219].
Molecules 30 03264 sch012
Scheme 13. Co-catalyzed annulation of terminal alkynes and o-phenylenediamines [224].
Scheme 13. Co-catalyzed annulation of terminal alkynes and o-phenylenediamines [224].
Molecules 30 03264 sch013
Scheme 14. Cyclisation reactions of 35 with allylamine and propargylamine [235].
Scheme 14. Cyclisation reactions of 35 with allylamine and propargylamine [235].
Molecules 30 03264 sch014
Scheme 15. Synthesis via a Knoevenagel/[4+1] cycloaddition cascade [236].
Scheme 15. Synthesis via a Knoevenagel/[4+1] cycloaddition cascade [236].
Molecules 30 03264 sch015
Scheme 16. Microwave-assisted one-pot tandem reactions for direct conversion of primary aldehydes to triazines [241].
Scheme 16. Microwave-assisted one-pot tandem reactions for direct conversion of primary aldehydes to triazines [241].
Molecules 30 03264 sch016
Scheme 17. Condensation of acid chlorides or anhydrides 44 with salt 45 [242].
Scheme 17. Condensation of acid chlorides or anhydrides 44 with salt 45 [242].
Molecules 30 03264 sch017
Scheme 18. Copper-catalysed synthesis of substituted 2,4-diamino-1,3,5-triazines [243].
Scheme 18. Copper-catalysed synthesis of substituted 2,4-diamino-1,3,5-triazines [243].
Molecules 30 03264 sch018
Scheme 19. Reactivity of 1,2,3,5-tetrazines 50 [157].
Scheme 19. Reactivity of 1,2,3,5-tetrazines 50 [157].
Molecules 30 03264 sch019
Scheme 20. The transformations to construct 1,2,4-triazine derivatives [246].
Scheme 20. The transformations to construct 1,2,4-triazine derivatives [246].
Molecules 30 03264 sch020
Scheme 21. Synthesis of triazine derivative [247].
Scheme 21. Synthesis of triazine derivative [247].
Molecules 30 03264 sch021
Scheme 22. Multistep synthesis of pyrrolotriazine [248].
Scheme 22. Multistep synthesis of pyrrolotriazine [248].
Molecules 30 03264 sch022
Scheme 23. Two-step synthesis of pyrrolotriazine [249].
Scheme 23. Two-step synthesis of pyrrolotriazine [249].
Molecules 30 03264 sch023
Scheme 24. The base-mediated cyclisation of (Z)-2,4-diazido-2-alkenoates [250].
Scheme 24. The base-mediated cyclisation of (Z)-2,4-diazido-2-alkenoates [250].
Molecules 30 03264 sch024
Scheme 25. The [5+1] cycloaddition reaction for the directed synthesis of triazine-1-oxides [251].
Scheme 25. The [5+1] cycloaddition reaction for the directed synthesis of triazine-1-oxides [251].
Molecules 30 03264 sch025
Scheme 26. Synthesis of 1,2,3,4-tetrazine [254].
Scheme 26. Synthesis of 1,2,3,4-tetrazine [254].
Molecules 30 03264 sch026
Scheme 27. (a,b) Two different methods of synthesis of cyclopenta-annulated 1,2,3,4-tetrazines [255].
Scheme 27. (a,b) Two different methods of synthesis of cyclopenta-annulated 1,2,3,4-tetrazines [255].
Molecules 30 03264 sch027
Scheme 28. Reaction of 3H-chromeno [2,3-d]pyrimidine with sodium azide [256].
Scheme 28. Reaction of 3H-chromeno [2,3-d]pyrimidine with sodium azide [256].
Molecules 30 03264 sch028
Scheme 29. Cycloadditions of aryl-N-sulphinylamines with substituted triazolium imides [258].
Scheme 29. Cycloadditions of aryl-N-sulphinylamines with substituted triazolium imides [258].
Molecules 30 03264 sch029
Scheme 30. Synthesis of a monocyclic aromatic 1,2,3,5-tetrazine [259].
Scheme 30. Synthesis of a monocyclic aromatic 1,2,3,5-tetrazine [259].
Molecules 30 03264 sch030
Scheme 31. Synthesis of 1,2,3,5-tetrazines [157].
Scheme 31. Synthesis of 1,2,3,5-tetrazines [157].
Molecules 30 03264 sch031
Scheme 32. Pinner’s synthesis mechanism [264].
Scheme 32. Pinner’s synthesis mechanism [264].
Molecules 30 03264 sch032
Scheme 33. One-pot catalysed synthesis of 1,2,4,5-tetrazines directly from nitriles [265].
Scheme 33. One-pot catalysed synthesis of 1,2,4,5-tetrazines directly from nitriles [265].
Molecules 30 03264 sch033
Scheme 34. Synthesis of s-tetrazines [266].
Scheme 34. Synthesis of s-tetrazines [266].
Molecules 30 03264 sch034
Scheme 35. Solid-phase synthesis of s-tetrazines [267].
Scheme 35. Solid-phase synthesis of s-tetrazines [267].
Molecules 30 03264 sch035
Scheme 36. Two-step synthesis of conjugated s-tetrazine derivatives [268].
Scheme 36. Two-step synthesis of conjugated s-tetrazine derivatives [268].
Molecules 30 03264 sch036
Scheme 37. Synthesis of pyrrolo[1,2-b][1,2,4,5]tetrazine [269,270,271].
Scheme 37. Synthesis of pyrrolo[1,2-b][1,2,4,5]tetrazine [269,270,271].
Molecules 30 03264 sch037
Scheme 38. Assembly of fused pyrrolopyrazinotetrazine ensembles and reversible fragmentation [272].
Scheme 38. Assembly of fused pyrrolopyrazinotetrazine ensembles and reversible fragmentation [272].
Molecules 30 03264 sch038
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gyrgenova, E.A.; Titova, Y.Y.; Ivanov, A.V. Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds—Part 1: Aromatic Frameworks. Molecules 2025, 30, 3264. https://doi.org/10.3390/molecules30153264

AMA Style

Gyrgenova EA, Titova YY, Ivanov AV. Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds—Part 1: Aromatic Frameworks. Molecules. 2025; 30(15):3264. https://doi.org/10.3390/molecules30153264

Chicago/Turabian Style

Gyrgenova, Elena A., Yuliya Y. Titova, and Andrey V. Ivanov. 2025. "Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds—Part 1: Aromatic Frameworks" Molecules 30, no. 15: 3264. https://doi.org/10.3390/molecules30153264

APA Style

Gyrgenova, E. A., Titova, Y. Y., & Ivanov, A. V. (2025). Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds—Part 1: Aromatic Frameworks. Molecules, 30(15), 3264. https://doi.org/10.3390/molecules30153264

Article Metrics

Back to TopTop